

# Lawrence Berkeley National Laboratory

## Biological Systems & Engineering

### Title

The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice

### Permalink

<https://escholarship.org/uc/item/77f5s184>

### Journal

Nature Metabolism, 3(12)

### ISSN

2522-5812

### Authors

Xu, Qixia  
Fu, Qiang  
Li, Zi  
[et al.](#)

### Publication Date

2021-12-01

### DOI

10.1038/s42255-021-00491-8

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



OPEN

# The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice

Qixia Xu<sup>1,2,11</sup>, Qiang Fu<sup>3,11</sup>, Zi Li<sup>4</sup>, Hanxin Liu<sup>3</sup>, Ying Wang<sup>1</sup>, Xu Lin<sup>4</sup>, Ruikun He<sup>5</sup>, Xuguang Zhang<sup>5</sup>, Zhenyu Ju<sup>6</sup>, Judith Campisi<sup>7,8</sup>, James L. Kirkland<sup>9</sup> and Yu Sun<sup>1,2,3,4,10</sup> ✉

**Ageing-associated functional decline of organs and increased risk for age-related chronic pathologies is driven in part by the accumulation of senescent cells, which develop the senescence-associated secretory phenotype (SASP). Here we show that procyanidin C1 (PCC1), a polyphenolic component of grape seed extract (GSE), increases the healthspan and lifespan of mice through its action on senescent cells. By screening a library of natural products, we find that GSE, and PCC1 as one of its active components, have specific effects on senescent cells. At low concentrations, PCC1 appears to inhibit SASP formation, whereas it selectively kills senescent cells at higher concentrations, possibly by promoting production of reactive oxygen species and mitochondrial dysfunction. In rodent models, PCC1 depletes senescent cells in a treatment-damaged tumour microenvironment and enhances therapeutic efficacy when co-administered with chemotherapy. Intermittent administration of PCC1 to either irradiated, senescent cell-implanted or naturally aged old mice alleviates physical dysfunction and prolongs survival. We identify PCC1 as a natural senotherapeutic agent with in vivo activity and high potential for further development as a clinical intervention to delay, alleviate or prevent age-related pathologies.**

Ageing is one of the biggest risk factor for chronic disorders, including cardiovascular diseases, metabolic disorders, neurodegenerative pathologies and diverse malignancies, which together account for the bulk of morbidity, mortality and health costs globally<sup>1</sup>. Considerable progress has been made over recent years to develop specific agents to treat individual age-related conditions, such as type 2 diabetes, osteoporosis, skeletal fragility and vascular dysfunction. However, the combined effect of these drugs in controlling morbidity and mortality of chronic diseases has been modest, and these diseases tend to occur in synchrony as multimorbidities, with prevalence increasing exponentially after 70 years of age<sup>2</sup>.

Several major factors affecting healthspan and lifespan have been identified through studies across a range of species and defined as ageing mechanisms that can be categorized into nine hallmarks<sup>3</sup>. Of these fundamental ageing mechanisms, cellular senescence has received substantial attention, as it represents a druggable process that prevents or delays multiple ageing comorbidities<sup>4</sup>. First reported in the 1960s, cellular senescence refers to a cellular state involving essentially irreversible replicative arrest, profound chromatin changes, apoptosis resistance and increased protein synthesis, frequently culminating in overproduction of pro-inflammatory cytokines, a feature termed the SASP, which is thought to drive ageing phenotypes and various age-related pathologies<sup>5</sup>. Ablation of senescent cells positive for the senescence marker p16<sup>INK4A</sup> mitigates tissue degeneration and extends animal healthspan, supporting the contention that senescent cells play a causative role in organismal ageing<sup>6,7</sup>.

Success in preclinical studies has inspired the initiation of proof-of-concept clinical trials involving senolytics for several human diseases with the potential to decrease the burden of in vivo senescent cells through selective pharmacological elimination<sup>8–10</sup>. Since the first discovery in 2015 (ref. <sup>11</sup>), a handful of synthetic or small-molecule senolytic agents are now known. Targeting strategies are mainly based on the resistance mechanism of senescent cells to apoptosis, which appears to depend on senescence-associated anti-apoptotic pathways that allow senescent cell survival for extended periods<sup>12,13</sup>. Intermittent administration of senolytics holds the potential to reduce the risk of patients developing adverse conditions, minimize off-target effects of drugs and prevent development of drug resistance of senescent cells, which do not divide, a characteristic that sets them apart from cancer cells, as cancer cells frequently acquire advantageous mutations providing resistance against anticancer therapies. However, most reported senolytics are dependent on cell lineage or cell type or, alternatively, exhibit substantial cytotoxicity in vivo, thus limiting their potential use for clinical purposes.

In this study, we screened a natural product medicinal library composed of anti-ageing agents and identified several candidates including GSE. Further analysis revealed that PCC1, a B type trimer epicatechin component of GSE flavonoids, plays a major role in inhibiting SASP expression at low concentrations and killing senescent cells at higher concentrations, the latter through inducing apoptosis. Preclinical data suggested that, in combination with classic chemotherapy, PCC1 can significantly reduce tumour size and prolong survival in several mouse models. Thus, PCC1

<sup>1</sup>CAS Key Laboratory of Tissue Microenvironment and Tumour, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China. <sup>2</sup>Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine & Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. <sup>3</sup>Department of Pharmacology, Institute of Aging Medicine, Binzhou Medical University, Yantai, China. <sup>4</sup>Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China. <sup>5</sup>Science & Technology Centre, By-Health Corp. Ltd., Guangzhou, China. <sup>6</sup>Key Laboratory of Regenerative Medicine of Ministry of Education, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Institute of Aging and Regenerative Medicine, Jinan University, Guangzhou, China. <sup>7</sup>Buck Institute for Research on Aging, Novato, CA, USA. <sup>8</sup>Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA. <sup>9</sup>Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA. <sup>10</sup>Department of Medicine and VAPSHCS, University of Washington, Seattle, WA, USA. <sup>11</sup>These authors contributed equally: Qixia Xu, Qiang Fu. ✉e-mail: [sunyu@sibs.ac.cn](mailto:sunyu@sibs.ac.cn)

represents a new class of phytochemical senolytics isolated from natural sources that delay ageing and ameliorate age-related disorders and warrants further exploration as a potential geroprotective agent in clinical medicine.

## Results

**Low concentrations of GSE restrain SASP expression.** In an effort to identify new compounds that can effectively modulate senescent cells, unbiased agent screening was performed with a phytochemical library composed of 46 plant-derived medicinal agents (PDMA library). We employed a primary normal human prostate stromal cell line, PSC27, as a cell-based model for this purpose. Composed mainly of fibroblasts but with a minor percentage of non-fibroblast cell lineages including endothelial cells and smooth muscle cells, PSC27 is a primary cell line per se and develops a typical SASP after exposure to stressors such as genotoxic chemotherapy or ionizing radiation<sup>14–17</sup>. We treated these cells with a pre-optimized sublethal dose of bleomycin (50  $\mu\text{g ml}^{-1}$ ) and observed increased senescence-associated  $\beta$ -galactosidase (SA- $\beta$ -Gal) staining, decreased 5-bromodeoxyuridine incorporation and elevated DNA-damage repair (DDR) foci 7–10 d after (Supplementary Fig. 1a–c). We set up a screening strategy to compare the effects that individual medicinal products had on the survival and expression profile of senescent cells (Extended Data Fig. 1a).

One promising advantage of senolytic agents is to selectively induce programmed death of senescent cells, such as ABT-263, ABT-737 and the combined use of dasatinib and quercetin<sup>11,18,19</sup>. We first tested the efficacy of these geroprotective drugs against senescent PSC27 cells to demonstrate its potential as an experimental cell model for drug screening. Our preliminary data suggested that each of these compounds significantly depleted senescent cells but not proliferating cells, thus confirming the feasibility of using this stromal line for further studies (Extended Data Fig. 1b). Upon large-scale screening of the PDMA library, we identified several compounds with the potential to selectively kill senescent cells in culture (Extended Data Fig. 1c–e).

Among the agents showing preliminary anti-senescence effects were GSE, quercetin, fisetin, curcumin and piperlongumine (Extended Data Fig. 1d,e). Quercetin and fisetin share similar chemical structures, exert similar medicinal effects and are both known senolytics<sup>11,20,21</sup>. Curcumin and piperlongumine are also natural compounds with recently discovered senolytic potential<sup>22,23</sup>. We chose to focus on GSE, which remained a largely underexplored source. Under in vitro conditions, GSE suppressed the SASP with maximal efficiency at 0.1875  $\mu\text{g ml}^{-1}$  (Extended Data Fig. 2a), which fits with the property of senomorphics<sup>24</sup>. Lower or higher concentrations of GSE were less efficacious, perhaps due to the induction of cellular stress responses as a result of increased cytotoxicity (Extended

Data Fig. 2a). Using RNA-seq, we found that treatment with GSE significantly altered the expression profile of senescence cells, with 2,644 genes downregulated and 1,472 genes upregulated at a fold change of 2.0 per gene ( $P < 0.01$ ) (Extended Data Fig. 2b). Although expression of a few genes unrelated to the SASP showed a similar tendency as that of typical SASP factors (Extended Data Fig. 2c), data from our gene set enrichment analysis (GSEA) supported reduced expression of molecular signatures of the SASP or activation of the nuclear factor (NF)- $\kappa\text{B}$  complex, which is a key mediator of the pro-inflammatory phenotype (Extended Data Fig. 2d,e).

Nuclear translocation of p65, one of the major subunits of the NF- $\kappa\text{B}$  complex, was observed in senescent cells, consistent with its functional engagement in SASP expression<sup>14</sup> (Extended Data Fig. 2f). Of note, this tendency was substantially antagonized by GSE at low concentrations (such as 0.1875  $\mu\text{g ml}^{-1}$ ). Conversely, activation of NF- $\kappa\text{B}$  signalling was not suppressed but rather appeared enhanced when GSE was used at higher concentrations (such as 3.7500  $\mu\text{g ml}^{-1}$ ), suggesting differential responses of senescent cells in these treatment conditions. Activation of DDR signalling, as evidenced by phosphorylation of ATM kinase in nuclear fractions, and expression of the C–X–C motif chemokine ligand (CXCL)8, one of the SASP hallmark factors, as observed in cytoplasmic fractions, were consistent with NF- $\kappa\text{B}$  activation in these settings (Extended Data Fig. 2f).

Protein–protein interaction profiling revealed a highly active network involving multiple factors significantly upregulated upon cellular senescence but downregulated once cells were exposed to GSE (Extended Data Fig. 3a). Gene ontology profiling revealed that these molecules are functionally engaged in biological processes and associated with cellular components generally consistent with the secreted nature of the SASP (Extended Data Fig. 3b,c). Thus, GSE is a natural product that holds the potential to control the pro-inflammatory profile of senescent cells, the SASP, when used within a specific concentration range. Although GSE was not the only natural product with senolytic efficacy in our cell-based assays (Extended Data Fig. 1d,e), our subsequent study largely focused on GSE, as its geroprotective capacity appeared particularly striking.


**GSE has senolytic activity at high concentrations.** Given the efficacy of GSE in reducing the SASP as a senomorphic agent, we next interrogated the potential of this natural product in killing senescent cells at higher concentrations by acting as a senolytic. SA- $\beta$ -Gal staining indicated that senescent cells were eliminated at a GSE concentration of 0.75  $\mu\text{g ml}^{-1}$  (Fig. 1a,b). At 3.75  $\mu\text{g ml}^{-1}$  GSE, a plateau of 20% senescent cell survival was reached (Fig. 1a,b).

Cell viability assays showed that GSE induced senescent cell death but not proliferating cell death starting from a concentration

**Fig. 1 | Characterisation of the capacity of GSE to eliminate senescent cells.** **a**, Quantification of senescent PSC27 cell survival by SA- $\beta$ -Gal positivity. GSE was applied to the medium at increasing concentrations. CTRL, control (proliferating) cells; SEN, senescent cells; NS, not significant. *P* values were calculated by one-way ANOVA with Tukey's multiple-comparison test. **b**, Representative images displaying SA- $\beta$ -Gal staining after treatment of PSC27 cells with different concentrations of GSE. Scale bar, 20  $\mu\text{m}$ . Data are representative of three independent experiments. DMSO, dimethylsulphoxide. **c**, Survival analysis of control and senescent PSC27 cells upon treatment with GSE (at concentrations of 0.3750, 0.7500, 1.8750, 3.7500, 7.5000 and 15.0000  $\mu\text{g ml}^{-1}$ , respectively). Data are shown as mean  $\pm$  s.d. and were derived from three biological replicates ( $n = 3$  independent assays). *P* values were calculated by two-sided *t*-tests. **d**, Time course measurement of in vitro viability upon treatment of control and senescent PSC27 cells with GSE (3.75  $\mu\text{g ml}^{-1}$ ). Data are shown as mean  $\pm$  s.d. and were derived from three biological replicates ( $n = 3$  independent experiments). *P* values were calculated by two-sided *t*-tests. **e**, Flow cytometry measurement of control and senescent PSC27 cells after processing with an annexin V-FITC and propidium iodide (PI) kit and 4,6-diamidino-2-phenylindole (DAPI) staining to determine the extent of apoptosis. Q1–Q4, quartiles 1–4. **f**, Comparative quantification of the percentage of viable (Q4, PI<sup>−</sup>annexin V<sup>−</sup>) and apoptotic (Q2 and Q3, PI<sup>+</sup>annexin V<sup>+</sup> and PI<sup>−</sup>annexin V<sup>+</sup>, respectively) cells in control or senescent populations treated with vehicle or GSE for 3 d ( $n = 3$  biologically independent assays). *P* values were calculated by two-sided *t*-tests. **g**, Measurement of the fluorescence signal of MitoSOX Red, a mitochondrial superoxide indicator, in PSC27 cells under different conditions. *P* values were calculated by two-sided *t*-tests. **h**, High-resolution mass spectra showing the total ion chromatogram (TIC) and base peak chromatogram of GSE after performing HPLC-ESI-QTOF-MS. Unless otherwise indicated, cells were subjected to relevant analyses 3 d after GSE treatment in the culture condition. cps, counts per second. Data in bar graphs and regression curves are shown as mean  $\pm$  s.d. and are representative of three biological replicates. NS,  $P > 0.05$ ; \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ .

of  $0.75 \mu\text{g ml}^{-1}$  (Fig. 1c). At a concentration of  $7.50 \mu\text{g ml}^{-1}$ , the percentage of surviving senescent cells declined to approximately 10%, whereas the viability of proliferating cells was not affected even at

$15.00 \mu\text{g ml}^{-1}$  GSE (Fig. 1c), the highest concentration used in our cell assays, suggesting prominent selectivity and specificity of GSE against senescent cells, which are major traits of senolytics.





We next measured the capacity of GSE to differentially target senescent cells in a time course. Upon treatment with GSE at a concentration of  $3.75 \mu\text{g ml}^{-1}$ , the viability of senescent cells did not significantly decrease until after 20 h. The difference in viability between senescent cells and the control (proliferating cells) reached a maximum after 32 h, implying heterogeneity of intrinsic resistance to senolytics in senescent cell populations (Fig. 1d).

As GSE generates distinct effects against senescent cells, we analysed the efficacy of GSE in inducing cell apoptosis. Flow cytometry demonstrated significantly reduced viability, while apoptosis of senescent cells but not that of proliferating cells was elevated (Fig. 1e,f and Supplementary Fig. 2a). Mitochondrial dysfunction and metabolic changes are among the hallmarks of senescent cells and organismal ageing, events causing oxidative stress and production of reactive oxygen species (ROS) such as superoxide<sup>3,25</sup>. We used MitoSOX Red, a mitochondrial superoxide indicator<sup>26</sup>, to probe intercellular changes and found that GSE promoted the generation of mitochondrial ROS in senescent cells but not in proliferating cells (Fig. 1g). Thus, our data are consistent with a model in which GSE kills senescent cells through induction of apoptosis and exacerbation of mitochondrial stress in vitro.

Grape seeds amount to 38–52%, on a dry matter basis, of grapes and constitute a copious source of antioxidants<sup>27</sup>. We applied high pressure liquid chromatography (HPLC) coupled to quadrupole time-of-flight mass spectrometry (QTOF-MS) equipped with an electrospray ionisation (ESI) interface to identify major components of GSE. We found three major categories of phytochemicals, including phenolic acids, flavonoids (such as flavan-3-ol, procyanidins) and other compounds (Fig. 1h and Supplementary Table 1). Among them, a few components were identified as procyanidins and their derivatives, which were reported to target mitochondrial proteins and alleviate multiple chronic diseases<sup>28</sup>. However, the major component(s) mediating the senolytic function of GSE remains largely unclear.

**The PCC1 component of GSE has senolytic activity.** Reported biological activities of grape seed procyanidins include reduction of oxidative damage, suppression of inflammation and induction of cancer cell apoptosis<sup>29–32</sup>. Among individual compounds found in GSE, PCC1 warrants special attention, as it was shown to induce DNA damage, cause cell cycle arrest and increase expression of checkpoint kinases<sup>33</sup>. Data from preliminary analysis (total ion chromatogram) of GSE, a mixture of phytochemical agents per se, by HPLC–QTOF-MS suggested the presence of PCC1, as the profile of GSE at specific MS peaks matched with the chromatogram profile of chemically pure PCC1 acquired from a commercial source (Fig. 1h and Supplementary Fig. 2b).

PCC1 was shown to decrease the level of BCL-2 but increase expression of the regulator BAX and activities of caspases 3 and 9 in cultured cancer cells, thus potentially generating anticancer effects through induction of apoptosis<sup>33</sup>. Hence, we next assessed the

capacity and selectivity of PCC1 to eliminate senescent cells in culture. The data suggest that PCC1 is senolytic for senescent stromal cells starting at a concentration of  $50 \mu\text{M}$ , at which proliferating cells remain largely unaffected (Fig. 2a,b and Supplementary Table 2). Although higher concentrations caused a lower survival rate of senescent cells, with a threshold approximately at  $200 \mu\text{M}$ , PCC1 only exhibited toxicity toward control cells when used at  $600 \mu\text{M}$  or higher (Fig. 2b). A time course of caspase 3/7 activity indicated that PCC1 exerted apoptotic effects within 12 h, reaching a plateau at 24 h (Fig. 2c). This finding was largely consistent with viability measurements (Fig. 2d). The senolytic nature of PCC1 was confirmed by cells that entered senescence due to replicative exhaustion or senescence (RS) or oncogene (HRAS<sup>G12V</sup>) overexpression (OIS), which generates stressful insults similar to those of therapy-induced senescence (Fig. 2e, Extended Data Fig. 4b–e and Supplementary Table 2). Together, the results suggest that PCC1 selectively clears senescent human stromal cells induced by different stimuli in a dose-dependent manner but without a significant effect on non-senescent cells when used at appropriate concentrations.

To experimentally expand and establish PCC1 efficacy across cell lineages, we treated human foetal lung fibroblasts (WI38), primary human umbilical vein endothelial cells (HUVECs) and human mesenchymal stem cells (MSCs) with PCC1 and found that senescent cells of all these lineages exhibited similar susceptibility for selective ablation by PCC1, whereas their nonsenescent counterparts remained viable (Extended Data Fig. 4f–h and Supplementary Table 3). We further confirmed the induction of apoptosis in senescent cells in response to PCC1 by flow cytometry, whereas proliferating cells remained largely unaffected by PCC1 (Fig. 2f,g). In sum, our data show that PCC1 selectively eliminates senescent cells across various cell types and arising from different triggers of senescence.

To visualize the depletion of senescent cells by PCC1, we examined expression of p16<sup>INK4a</sup>, a widely used marker of senescence, in stromal cells that experienced RS. PCC1 effectively removed p16-positive senescent cells, which only appeared in late-passage PSC27 populations, with an efficacy largely resembling that of ABT-263 ( $1.25 \mu\text{M}$ ), a well-established synthetic senolytic agent<sup>18,21</sup> (Fig. 2h,i).


To substantiate that PCC1-mediated elimination of senescent cells occurs mainly through induction of apoptosis, rather than through other forms of programmed cell death, we treated cells with the pan-caspase apoptosis inhibitor quinolyl-valyl-O-methylaspartyl-(2,6-difluorophenoxy)-methylketone (QVD-Oph). The ability of PCC1 to kill senescent cells was reversed by QVD-Oph. PCC1 thus shares its caspase-dependent induction of apoptosis as a senolytic feature with ABT-263 (Fig. 2j). Further analysis with chemical inhibitors excluded PCC1-induced cell death through ferroptosis, pyroptosis or necroptosis (Extended Data Fig. 4i).

To assess the potential of cell population doubling (PD) after treatment with genotoxic drugs, we employed MSCs, which can self-renew and resume colony-based proliferation even after

**Fig. 2 | Characterisation of the senolytic potential of PCC1.** **a**, Measurement of senescent PSC27 cell survival by SA- $\beta$ -Gal staining. PCC1 was applied at increasing concentrations. *P* values were calculated by one-way ANOVA with Tukey's multiple-comparison test. **b**, Survival of senescent PSC27 cells induced by bleomycin at increasing PCC1 concentrations. **c**, Apoptotic assay for caspase 3/7 activity. **d**, Time course survival curves to assess PSC27 cell viability after PCC1 treatment. **e**, Images of SA- $\beta$ -Gal staining. TIS, therapy-induced senescence (by bleomycin). Scale bar,  $20 \mu\text{m}$ . Data are representative of three independent experiments. **f**, Flow cytometry after processing with an annexin V-FITC and PI kit and DAPI staining to determine apoptosis levels. **g**, Quantification of the percentage of viable (Q4, PI<sup>-</sup>annexin V<sup>-</sup>) and apoptotic (Q2 and Q3, PI<sup>+</sup>annexin V<sup>+</sup> and PI<sup>-</sup>annexin V<sup>+</sup>, respectively) cells after treatment with vehicle or PCC1 for 3 d ( $n=3$  biologically independent assays). **h**, Immunofluorescence staining of PSC27 cells. RS was induced by serial passaging before PCC1 treatment. Red, p16<sup>INK4a</sup>. Cells at an early passage (P10) were used as a negative control. ABT-263 ( $1.25 \mu\text{M}$ ) was tested as a positive control. Scale bar,  $20 \mu\text{m}$ . **i**, Statistics of immunofluorescence staining. **j**, PCC1-induced senolytic activity after pan-caspase inhibition ( $20 \mu\text{M}$  QVD-Oph). **k**, PD assay of human MSCs. PCC1 was applied on the 8th day after the beginning of experiments as indicated. BLEO, bleomycin. For **c,d,k**, data are shown as mean  $\pm$  s.d. and were derived from three biological replicates ( $n=3$  independent assays). For data in **b-d,g,i,j**, *P* values were calculated by two-sided *t*-tests. In experiments for **c-k**, PCC1 was used at  $100 \mu\text{M}$ . Unless otherwise indicated, samples were collected for analyses 3 d after PCC1 treatment. Data in bar graphs are shown as mean  $\pm$  s.d. and are representative of three biological replicates. NS,  $P>0.05$ ; \* $P<0.05$ ; \*\* $P<0.01$ ; \*\*\* $P<0.001$ ; \*\*\*\* $P<0.0001$ .

exposure to environmental stresses<sup>34</sup>, likely due to the heterogeneity of damage, with cells experiencing less damage presumably able to retain the potential to self-recover and re-enter the cell cycle<sup>34,35</sup>.

Unlike bleomycin-damaged cells, which rapidly entered growth arrest after treatment, post-senescence treatment with PCC1 significantly enhanced the PD capacity of MSCs, especially after removal



of senescent cells developing the SASP and holding the potential to induce paracrine senescence within cell populations (Fig. 2k). However, treatment with PCC1 did not affect the PD of proliferating cells, further indicative of the selectivity of PCC1 for senescent cells compared with their normal counterparts.

As GSE is a complex phytochemical mixture, with many of its components having reported antioxidant and anti-inflammatory activities<sup>27,36</sup>, we investigated whether PCC1 was the principal constituent of GSE involved in depleting senescent cells or whether alternative phytochemicals in GSE could contribute to its overall senolytic effect. To this end, we examined the influence of individual phytochemical molecules on the survival of senescent PSC27 cells. Most GSE components failed to display senolytic activity in the dose range of PCC1 and did not cause significant death of proliferating cells (Supplementary Figs. 3 and 4). Although the flavonoid quercetin showed senolytic activity as in our previous studies, a property shared with natural flavones<sup>11,21</sup>, 'reconstituted GSE', consisting of the major components mixed according to their mass percentage as revealed by our HPLC-QTOF-MS data (Supplementary Table 1, note that quercetin accounts for only 0.9%) but purposefully excluding PCC1, did not show similar results as those observed for PCC1 in both assays (Supplementary Figs. 3 and 4). Although we cannot conclude whether other components have a contribution, our data clearly suggest that PCC1 is a primary mediator of the senolytic effect of GSE.

### PCC1 induces mitochondrial dysfunction in senescent cells.

Given the prominent efficacy of PCC1 in selectively inducing senescent cell death, we interrogated the underlying mechanism(s). PCC1 belongs to the superfamily of flavonoids, which can scavenge free radicals, chelate metals and reduce hydroperoxide formation, antioxidant properties attributable to the functional '-OH' group in the structure and its position on the ring of the flavonoid molecule<sup>27</sup>. The antioxidant capacity of procyanidins is, in part, governed by their degree of polymerisation, while PCC1 is a procyanidin epicatechin trimer by nature (Fig. 3a).

We first analysed the impact of PCC1 on the transcriptome-wide expression of senescent cells. Bioinformatics showed that 4,406 genes were significantly upregulated and 2,766 genes were downregulated in stromal cells after PCC1 treatment (Supplementary Fig. 5a). We observed a large array of SASP factors, expression of which was markedly upregulated during cellular senescence but substantially downregulated when senescent cells were exposed to PCC1 (Fig. 3b). GSEA profiling showed that both the SASP and NF- $\kappa$ B signatures were remarkably suppressed by PCC1 treatment (Fig. 3c,d). We further noticed multiple mutual interactions or functional connections between these factors upregulated during senescence and downregulated after PCC1 treatment appearing

in the list of top differentially expressed genes, most of which were typically secreted factors (Fig. 3e).


To understand the selectivity of PCC1 for senescent cells, we further assessed the transcriptomic expression profile and noticed that PCC1 induced expression changes in a few BCL-2 superfamily members (Fig. 3f). Although DDR signalling remained largely unaffected, PCC1-dependent upregulation or activation of p38 mitogen-activated protein kinase (MAPK) was observed, with caspase 3 cleavage occurring in these cells (Fig. 3g). Although BCL-xL expression was elevated in senescent cells relative to that in their proliferating controls, PCC1 treatment did not further enhance its protein level. Levels of the other two BCL-2 factors, namely, BCL-2 and BAX, remained largely unchanged. While NOXA and PUMA (two members of the BCL-2 homology domain 3 (BH3)-only pro-apoptotic subfamily) exhibited different expression patterns during cellular senescence, PCC1 treatment resulted in the upregulation of both factors (Fig. 3g).

Knockdown of BCL-2 pro-apoptotic factors suggested that NOXA and PUMA partially mediated the senolytic actions of PCC1 (Fig. 3h and Extended Data Fig. 5a-c). Treatment with chemical inhibitors of AKT kinase, Janus kinase (JAK)1, JAK2 and p38 MAPK signalling also suggested involvement of these signalling pathways in expression of *PMAIP1* (NOXA) and *BBC3* (PUMA) and senescent cell apoptosis after PCC1 treatment (Fig. 3i-m).

As knocking down NOXA and PUMA only partially inhibited the senolytic effect of PCC1 (Fig. 3h,k-m), we investigated other possible mechanism(s) leading to senescent cell death. Because procyanidins usually increase cell viability, decrease ROS production and restrain oxidative stress in mammalian cells<sup>37,38</sup>, we next asked whether similar or antioxidant effects could be observed in senescent cells exposed to PCC1. Surprisingly, we found that the opposite was the case, as senescent PSC27 cells displayed elevated ROS levels when treated with PCC1, in contrast to their proliferating counterparts (Fig. 4a and Extended Data Fig. 5d, note signals from the 2'-7'-dichlorodihydrofluorescein diacetate (DCFH-DA) probe). Treatment with HS-1793, a stable resveratrol analogue that has free radical-scavenging activity<sup>39</sup>, effectively blocked ROS production in senescent cells treated with PCC1 (Extended Data Fig. 5e,f), whereas ROS levels were further increased after exposure of PCC1-treated senescent cells to CCCP, a protonophore mitochondrial uncoupler<sup>40</sup>, or ruxotemide (LTX-315), an amphipathic cationic peptide that induces permeabilisation of the outer mitochondrial membrane<sup>41</sup>, each applied at concentrations that were not cytotoxic to control cells (Extended Data Fig. 5e,f). Although treatment with either CCCP or ruxotemide per se also caused enhanced ROS production, the effects were generally smaller than those induced by PCC1, suggesting that PCC1 triggers mitochondrial dysfunction in senescent cells. By measuring the apoptotic index of senescent cells

**Fig. 3 | PCC1 induces senescent cell apoptosis by engaging pro-apoptotic pathways.** **a**, Chemical structure of the trimeric epicatechin PCC1. **b**, Heatmap depicting top genes (50) significantly upregulated in senescent PSC27 cells but downregulated upon PCC1 treatment (50  $\mu$ M). Red stars, SASP factors. **c**, GSEA plot of a significant gene set in the SASP spectrum. FDR, false discovery rate; NES, normalized enrichment score. **d**, GSEA plot of a significant gene set associated with NF- $\kappa$ B-mediated signalling. **e**, NetworkAnalyst map of protein-protein interactions of typical SASP-associated factors significantly upregulated in senescent cells but downregulated by PCC1 treatment. **f**, Heatmap showing the differential expression of BCL-2 family genes in control, senescent and PCC1-treated senescent cells. **g**, Immunoblot of PSC27 cells exposed to different agents. Expression of pro-apoptotic and anti-apoptotic factors and DDR signalling-associated molecules was examined. Caspase 3 (t), total caspase 3; caspase 3 (c), cleaved caspase 3; p, phosphorylated.  $\beta$ -actin and GAPDH, loading controls. Data are representative of three independent experiments. **h**, Cells were infected with three different short hairpin RNA species targeting NOXA or PUMA before being exposed to bleomycin to induce senescence. Seven days later, cells were treated with PCC1 (100  $\mu$ M) for a 3-d period to induce apoptosis. SCR, scramble. **i**, NOXA expression was determined using quantitative PCR with reverse transcription (RT-qPCR). Cells were treated with bleomycin to induce senescence before exposure to 100  $\mu$ M PCC1 for 3 d in the absence or presence of 10  $\mu$ M MK2206, 10  $\mu$ M ruxotemide or 20 nM BMS-582949 to inhibit the activity of AKT, JAK1 and/or JAK2 or p38 MAPK, respectively. **j**, A similar set of RT-qPCR expression assays for PUMA using conditions described in **i**. **k-m**, Measurement of cell viability after PCC1 treatment in the absence or presence of MK2206 (**k**), ruxotemide (**l**) or BMS-582949 (**m**), included to inhibit the enzymatic activity of AKT, JAK1 and/or JAK2 or p38 MAPK, respectively. For data in **c,d**, *P* values were calculated by one-way ANOVA with Tukey's post hoc comparison. Statistical significance in **h-m** was calculated using two-sided *t*-tests or one-way ANOVA (Dunnett's test). Data in all bar graphs are shown as mean  $\pm$  s.d. and represent three biological replicates. NS, *P* > 0.05; \**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001; \*\*\*\**P* < 0.0001.





(caspase 3/7 activity), we found that the PCC1-induced effect could be further enhanced upon combination of PCC1 with each mitochondrial disruptor but suppressed upon co-treatment with HS-1793 (Extended Data Fig. 5g).

Cytochrome c release and mitochondrial membrane disruption are intracellular events associated with apoptosis and often act as direct apoptotic drivers<sup>42</sup>. Our data suggest that PCC1 treatment enhanced cytochrome c release from mitochondria to the surrounding cytoplasmic space (Fig. 4b and Extended Data Fig. 5h). The release of cytochrome c from mitochondria is largely consistent with biochemical reactions such as caspase activation in PCC1-treated senescent cells (Fig. 3g).

Members of the procyanidin family exhibit a broad spectrum of pharmacological properties including anti-oxidation and anti-inflammation, which are the opposite of what we observed when treating senescent cells with PCC1. The current data prompted us to reason whether the effects of PCC1 are reproduced by other procyanidins. Procyanidin B2 (PCB2) is a representative flavonoid that exists as a dimer and reduces ROS levels during oxidative stress in cultured cells<sup>43</sup>. PCB2 failed to eliminate senescent cells (Fig. 4c and Supplementary Figs. 3b and 4b) and neither enhanced ROS production nor induced mitochondrial release of cytochrome c in senescent cells (Fig. 4d and Extended Data Fig. 5i). A substantial amount of p65 (RelA), one of the major subunits of the NF- $\kappa$ B complex, translocated to the nucleus of senescent cells (Fig. 4e). Although PCB2 treatment counteracted p65 nuclear translocation, which is consistent with its anti-inflammatory capacity, this effect was not reproduced by PCC1 (Fig. 4e). Senescent cells exposed to PCC1 exhibited remarkable caspase 3 cleavage, whereas those treated with PCB2 did not, further differentiating the biological activity of these two procyanidin molecules (Fig. 4e).

As a factor that functionally governs cell fate, p53 can induce apoptosis either by transactivating pro-apoptotic genes or in a transcription-independent manner by translocating to mitochondria<sup>44</sup>. We observed increased nuclear translocation of p53 upon cellular senescence, a pattern markedly reduced by PCC1, but much less so than that by PCB2 (Fig. 4e,f). As nuclear exclusion of p53 is a critical step in the induction of senescent cell apoptosis<sup>45</sup>, we further assessed the distribution of p53. Immunofluorescence staining indicated substantially increased overlap of p53 with cytochrome c oxidase subunit IV (COX IV) (a transmembrane protein complex in the mitochondrial respiratory electron chain, often used as a mitochondrial resident protein marker) in PCC1-treated senescent cells, suggesting enhanced translocation of p53 into the mitochondrial matrix. Although we observed some p53 in mitochondria of proliferating cells, PCC1 did not induce a remarkable or comprehensive influx of p53 protein into the mitochondrial matrix of proliferating cells (Fig. 4f). However, in

senescent cells, p53 levels were decreased in the nuclei but increased in mitochondria upon exposure to PCC1 (Fig. 4g).

Mitochondrial membrane potential ( $\Delta\psi$ m) decline is an event that can trigger apoptosis through the mitochondrial-mediated intrinsic pathway<sup>46</sup>. We found that  $\Delta\psi$ m was significantly reduced in senescent cells, while proliferating cells remained basically unaffected in the presence of PCC1, as indicated by the profile of JC-1 probe signals (Fig. 4h). Thus, PCC1 promotes ROS generation, triggers cytochrome c release and causes  $\Delta\psi$ m disturbance in senescent cells, events inherently associated with mitochondrial disability and functionally driving cell apoptosis.

Together, our experimental data suggest that senescent cells are subject to PCC1-induced apoptosis, a process partially mediated by NOXA and PUMA upregulation and associated with enhanced ROS production and mitochondrial dysfunction.

**PCC1 promotes tumour regression and reduces chemoresistance.** Given the capacity and selectivity of PCC1 for eliminating senescent cells in vitro, we next interrogated whether this agent could be exploited to intervene against age-related pathologies in vivo. In clinical oncology, drug resistance limits the efficacy of most anticancer treatments, while senescent cells frequently contribute to therapeutic resistance through development of an in vivo SASP in the drug-damaged tumour microenvironment (TME)<sup>15,16,47</sup>. Pharmacological elimination of therapy-induced senescent cells minimizes side effects of chemotherapy and prevents cancer recurrence in animals<sup>48</sup>. However, the feasibility of PCC1-mediated depletion of senescent cells from primary tumours to enhance the efficacy of anticancer treatments remains largely unknown.

First, we chose to build tissue recombinants by admixing PSC27 cells with PC3 cells, which are a typical prostate cancer cell line of high malignancy, at a pre-optimized ratio (1:4)<sup>44</sup>. The cells were then subcutaneously implanted into the hind flank of mice with non-obese diabetes and severe combined immunodeficiency (NOD-SCID). Tumours of animals were measured at the end of an 8-week period, and tissues were acquired for pathological appraisal. Compared to tumours comprising PC3 cancer cells and naive PSC27 stromal cells, xenografts composed of PC3 cells and senescent PSC27 cells exhibited significantly increased volume, confirming the tumour growth-promoting effects of senescent cells (Extended Data Fig. 6a).

To mimic clinical conditions, we experimentally designed a preclinical regimen incorporating genotoxic therapeutics and/or senolytics (Fig. 5a). Two weeks after subcutaneous implantation, when stable uptake of tumours in vivo was observed, a single dose of mitoxantrone (MIT, a chemotherapeutic drug) or placebo was delivered to animals on the 1st day of the 3rd, 5th and 7th weeks until the end of the 8-week regimen (Extended Data Fig. 6b). In


**Fig. 4 | PCC1-induced apoptosis is partially mediated through mitochondrial dysfunction.** **a**, Measurement of ROS levels with DCFH-DA, a cell-permeable fluorescent probe sensitive to changes in cellular redox state. Experiments were performed 1 d after PCC1 treatment. Left, representative images. Scale bar, 10  $\mu$ m. Right, statistics. DCF, dichlorodihydrofluorescein. **b**, Immunoblot after exposure of cells to different treatments. Cytochrome c distribution between mitochondria and the cytoplasm was profiled by isolating mitochondria from cytosol supernatants 3 d after PCC1 treatment. COX IV is the terminal enzyme of the mitochondrial respiratory chain and a mitochondrial marker. **c**, Time course survival curves to assess PSC27 cell viability upon treatment with PCB2, another member of the natural procyanidin family. Data are shown as mean  $\pm$  s.d. and were derived from three biological replicates ( $n=3$  independent assays). **d**, ROS-production assay performed in a similar manner as described in **a**, except that cells were exposed to PCB2. Scale bar, 10  $\mu$ m. **e**, Immunoblot of the expression and distribution of ATM, p53 and caspase 3 between the cytoplasm and the nucleus. GAPDH and lamin A/C, loading controls for cytoplasm and nuclei, respectively. C1, PCC1; B2, PCB2. **f**, Confocal microscopy of immunofluorescence staining after treatment of cells with vehicle (DMSO) or PCC1. Primary antibodies specific to p53 or COX IV were applied. Scale bar, 10  $\mu$ m. **g**, Immunoblot analysis of PSC27 cells exposed to different agents. Cyto, cytoplasmic; mito, mitochondrial. **h**, Analysis of JC-1 staining, a fluorescent probe indicative of  $\Delta\psi$ m. Signals were measured over 3 d. Green fluorescence indicates JC-1 monomers (they appear in the cytosol after mitochondrial membrane depolarisation and indicate early-stage apoptosis). Red fluorescence indicates JC-1 aggregation (resides on intact mitochondria). Left, representative images. Right, statistics. Both PCC1 and PCB2 were used at 100  $\mu$ M in relevant assays. Data in **b**, **e**–**g** are representative of three independent experiments. Statistical significance in **a** (right), **d** (right) and **h** (right) was calculated using two-sided *t*-tests, and that in **c** was calculated with one-way ANOVA (Dunnett's test). Data in all bar graphs are shown as mean  $\pm$  s.d. and are representative of three biological replicates. NS,  $P>0.05$ ; \* $P<0.05$ ; \*\* $P<0.01$ .



contrast to the placebo-treated group, MIT administration remarkably delayed tumour growth, validating the efficacy of MIT as a chemotherapeutic agent (44.0% reduction in tumour size) (Fig. 5b). Notably, although administration of PCC1 itself did not cause tumour shrinkage, treatment with MIT followed by PCC1 delivery (at 20 mg per kg via intraperitoneal (i.p.) injection 2 weeks after the first MIT dose and then delivered biweekly) remarkably enhanced tumour regression (55.2% reduction in tumour size compared with

MIT alone; 74.9% reduction in tumour volume compared with the placebo treatment) (Fig. 5b).

We next tested whether cellular senescence occurred in the tumour foci of these animals. Unsurprisingly, MIT administration induced the appearance of a large number of senescent cells in tumour tissue. However, delivery of PCC1 to these chemotherapy-treated animals depleted the majority of senescent cells (Fig. 5c,d). Laser capture microdissection followed by transcript assays indicated



significantly increased expression of SASP factors including *IL6*, *CXCL8*, *SPINK1*, *WNT16B* (also known as *WNT16*), *GM-CSF* (also known as *CSF2*), *MMP3* and *IL1A*, a tendency accompanied by upregulation of the gene encoding the senescence marker  $p16^{INK4a}$  in chemotherapy-treated animals (Fig. 5e and Extended Data Fig. 6c). These changes were mainly observed in stromal cells, rather than in neighbouring cancer cells, implying the possibility of repopulation of residual cancer cells, which frequently develop acquired resistance in the treatment-damaged TME. However, upon administration of PCC1, SASP-associated changes were largely reversed, as suggested by transcript assays and RNA-seq (Fig. 5f and Extended Data Fig. 6d).

To investigate the mechanisms underlying SASP expression in MIT-treated mice, we dissected tumours from animals treated with these two agents 7 d after the first dose of GSE delivery, a time point before the development of resistant colonies. In contrast to placebo treatment, MIT administration increased DNA damage and apoptosis, whereas treatment with PCC1 alone did not (Fig. 5g). However, when MIT-treated animals were co-administered PCC1, DNA damage and apoptosis were significantly augmented, implying enhanced cytotoxicity in animals receiving both chemotherapy and senolytics. As supporting evidence, we observed elevated caspase 3 cleavage, a typical hallmark of cellular apoptosis, when PCC1 was administered alongside MIT (Fig. 5h).

We next evaluated the consequences of tumour progression by comparing the survival of different animal groups over time. In this preclinical cohort, animals were monitored for tumour growth, with bulky disease considered to have arisen once the tumour burden was prominent (size  $\geq 2,000 \text{ mm}^3$ ), an approach employed in former studies<sup>14,49</sup>. Mice receiving the MIT–PCC1 combinatorial treatment showed the most prolonged median survival, surviving at least 48.1% longer than the group treated with MIT alone (Fig. 5i, green versus blue). However, PCC1 treatment alone only marginally extended survival. Our data suggest that PCC1 administration alone neither changes tumour growth nor promotes animal survival, whereas co-administration of PCC1 with MIT has significant synergistic effects.

Of note, treatments performed in these studies appeared to be well tolerated by animals, as no significant perturbations in urea, creatinine or liver enzyme levels or body weight were observed (Extended Data Fig. 6e,f). More importantly, chemotherapeutic and geroprotective agents administered at doses optimized in this study did not significantly interfere with the integrity of the immune system or tissue homeostasis of critical organs, even in immunocompetent mice (Supplementary Fig. 6a–c). These results support the rationale that anti-ageing agents combined with conventional chemotherapy have the potential to enhance tumour response without causing severe systemic toxicity.

**Senescent cell removal as a result of PCC1 treatment alleviates physical dysfunction.** Even a small number of senescent cells can induce physical dysfunction in young animals<sup>50</sup>. We asked whether PCC1 selectively kills senescent cells in vivo and can thereby prevent physical dysfunction. To address this question, we performed parallel implantation of control and senescent mouse embryonic fibroblasts (MEFs,  $0.5 \times 10^6$  cells per side) constitutively expressing luciferase ( $LUC^+$ ) subcutaneously into syngeneic wild-type (WT) mice. Immediately after implantation, animals were treated with PCC1 (at 20 mg per kg via i.p. injection) or vehicle (ethanol–polyethylene glycol 400–Phosal 50 propylene glycol (PG) at 10:30:60) for 7 d (Fig. 6a). We found that luminescence signal intensities were significantly lower in mice implanted with senescent cells and treated with PCC1 than those in vehicle-treated littermates, although no difference was observed following treatment of mice transplanted with  $LUC^+$  control cells (Fig. 6b,c), substantiating the senolytic efficacy of PCC1 in vivo.


We next investigated whether killing implanted senescent cells using PCC1 could attenuate pathological events, specifically physical dysfunction. Treating young animals with PCC1 after senescent cell implantation for 1 week prevented declines in maximal walking speed (RotaRod), hanging endurance (hanging test) and grip strength (grip metre), changes observed within 1 month after vehicle treatment of another group of mice carrying senescent cells, consistent with the potential of PCC1 to reduce physical dysfunction (Fig. 6d–f). PCC1 administration also prevented the physical dysfunction that occurred in animals 5 weeks following senescent cell implantation (Fig. 6g). In mice harbouring senescent cells, a single 5-d course of PCC1 treatment improved physical function compared to vehicle treatment (Fig. 6h–j). Of note, the improvement was detectable 2 weeks after PCC1 treatment and even lasted for several months (Extended Data Fig. 7a,b). At these two time points of PCC1 administration (immediately versus 5 weeks after senescent cell implantation), the beneficial effects of PCC1 seemed to be comparable. The data suggest that the timeline of PCC1 administration may be flexible, indicative of its potential clinical feasibility. As plant seed-derived procyanidins usually have elimination half-lives of  $<12 \text{ h}$ <sup>51,52</sup>, such a sustained improvement in physical function following a single course of PCC1 treatment circumvents the need for continuous treatment with the senolytic agent, further implying that the activity of PCC1 is sufficient to avert senescent cell-induced physical dysfunction.

We next sought to evaluate the impact of senescent cells or the benefit of their elimination in middle-aged animals. For this purpose, we employed 17-month-old C57BL/6J mice, which were implanted with control or senescent MEFs. Notably, survival of animals carrying senescent cells and receiving vehicle treatment in the following

**Fig. 5 | Senolysis by PCC1 in the damaged TME diminishes SASP-conferred cancer resistance.** **a**, Illustrative diagram of a preclinical regimen. Two weeks after subcutaneous implantation and in vivo uptake of tissue recombinants, NOD–SCID male mice received either single (mono) or combined (dual) agents in a metronomic schedule composed of several cycles. BLI, bioluminescence imaging. **b**, Statistical profiling of tumour end volumes. PC3 cells were xenografted alone or together with PSC27 cells into the hind flank of animals. **c**, Comparative evaluation of in vivo senescence by SA- $\beta$ -Gal staining. Tumours were freshly dissected after killing animals and processed as frozen sections for histological staining. Scale bars, 200  $\mu\text{m}$ . **d**, Violin plots depicting comparative statistics of SA- $\beta$ -Gal staining in tumour tissues. **e**, Transcript assay for in vivo expression of several canonical SASP factors in stromal cells isolated from tumours. Tissues from animals xenografted with both stromal and cancer cells were subjected to laser capture microdissection-supported isolation and subsequent processes. Data are representative of three biological replicates ( $n=10$  animals per group). Datasets are displayed as box-and-whisker plots, in which a box extends from the 25th to the 75th percentile with the median shown as a line in the middle and whiskers indicating smallest and largest values. **f**, Profiling of SASP transcripts in stromal cells. Signals corresponding to each factor were normalized to those from the vehicle-treated group. Note  $p16^{INK4a}$  is also known as *CDKN2A* and  $p21^{CIP1}$  is also known as *CDKN1A*. **g**, Statistical measurement of cells with DNA damage and apoptotic cells in biospecimens collected as described in **a,b**. Values are presented as the percentage of cells positively stained by immunohistochemistry (IHC) with antibodies specific to histone  $\gamma\text{H2AX}$  or caspase 3 (cleaved). For **b,d–g**, *P* values were calculated by two-sided *t*-tests. **h**, Representative IHC images of caspase 3 (cleaved, CC3) at the end of the therapeutic regimes. Scale bars, 100  $\mu\text{m}$ . **i**, Comparative survival of mice killed after the development of advanced bulky diseases. Survival duration was calculated from the time of recombinant tissue injection until animal death. MS, median survival. *P* values were calculated by two-sided log-rank (Mantel–Cox) tests. Data in **c,h** are representative of three independent experiments. Data in all bar graphs are shown as mean  $\pm$  s.d. and are representative of three biological replicates.

year was significantly lower than that of counterparts receiving PCC1 treatment, with a 2.4-fold higher risk of death (hazard ratio,  $P=0.0172$ ) (Fig. 6k). However, disease burden, tumour burden at

death and causes of death were not significantly different between mice treated with vehicle and those treated with PCC1 (Fig. 6l,m). These data suggest that a small number of senescent cells might





affect survival through a general process, such as accelerating the progression of ageing, rather than by causing any specific pathology or a few individual conditions. Augmenting the senescent cell burden results in physical dysfunction, a tendency that is associated with mid-age mortality but can be postponed by administration of senolytics such as PCC1.

**PCC1 sustains physical function and prolongs survival of aged mice.** Senolytics deplete senescent cells in diverse tissues and organs in various pathophysiological situations, most of which are correlated with ageing<sup>53</sup>. To further examine the effect of PCC1 on senescent cells in organisms and organismal ageing, we selected two independent animal models of *in vivo* senescence, including therapy-challenged mice and naturally ageing mice. First, we induced cellular senescence by exposing WT mice to whole-body irradiation (WBI) at a sublethal dose (5 Gy), a step followed by geroprotective treatment with PCC1 (20 mg per kg via *i.p.* injection) or vehicle (ethanol-polyethylene glycol 400-Phosal 50 PG at 10:30:60) (once per week) (Fig. 7a). Of note, animals that had undergone WBI manifested an abnormal body appearance, including markedly greyed hair, which, however, was largely reversed by PCC1 administration (Fig. 7b,c). SA- $\beta$ -Gal-positive senescent cells were induced *in vivo* in these animals, as evidenced by increased staining positivity in cardiac and pulmonary tissues (Fig. 7d,e). However, when we treated with PCC1 by *i.p.* injection, the percentage of SA- $\beta$ -Gal-positive cells in dissected tissues was significantly reduced, unlike that of vehicle-treated mice at the post-WBI stage (Fig. 7f,g). PCC1 treatment also decreased the expression of senescence markers and a subset of key SASP factors compared with vehicle treatment (Fig. 7h). In sum, the data suggest that PCC1 can effectively deplete SA- $\beta$ -Gal-positive cells, control SASP expression and minimize senescent cell burden under *in vivo* conditions in mice.

We then assessed the impact of preclinical treatments on the physical parameters of mice. As expected, WBI significantly compromised exercise capacity and muscle strength as measured by treadmill and grip strength assays in the vehicle group (Fig. 7i,j). By contrast, PCC1 administration provided substantial benefit, restoring these capacities. More importantly, PCC1 treatment increased the survival rate (Fig. 7k). Our results indicate that PCC1-induced elimination of SA- $\beta$ -Gal-positive senescent cells could be an effective strategy to alleviate senescence-related physical regression and reduce mortality in settings of premature ageing triggered by environmental stressors such as cytotoxic therapy.

We next sought to define the impact of senescent cells on physical function in naturally ageing animals. For this purpose, we treated normal 20-month-old WT mice with vehicle (ethanol-polyethylene glycol 400-Phosal 50 PG at 10:30:60) or PCC1 (20 mg per kg via *i.p.* injection) (once every 2 weeks) for 4 months (Fig. 8a). Histological evaluation revealed a significantly elevated percentage

of SA- $\beta$ -Gal-positive senescent cells in the kidney, liver, lung and prostate of aged animals, which was reversed by PCC1 treatment (Fig. 8b,c and Extended Data Fig. 8a–f). Results from physical testing showed that PCC1 alleviated physical dysfunction by enhancing maximal walking speed, hanging endurance, grip strength, treadmill endurance, daily activity and beam balance performance of animals administered PCC1 compared to those treated with vehicle (Fig. 8d–i). Body weight and food intake remained largely unchanged in PCC1-treated mice (Extended Data Fig. 8g,h). Notably, expression of the SASP was significantly reduced in tissues such as the lungs of aged mice treated with PCC1 compared to that in the vehicle-treated group (Fig. 8j), a pattern consistent with lesser secretion of SASP factors by human stromal tissues treated with PCC1 (Fig. 5f).

To establish the potential of senescent cell elimination to extend the remaining lifespan of WT mice, we performed PCC1 treatment beginning at a very old age (Fig. 8k). Mice receiving PCC1 administration (once every 2 weeks or biweekly) starting at 24–27 months of age (roughly equivalent to an age of 75–90 years in humans) had a 64.2% longer median post-treatment lifespan (or 9.4% longer overall lifespan) and lower mortality hazard (65.0%,  $P < 0.0001$ ) than the vehicle-treated group (Fig. 8l,m). These data indicate that PCC1 can significantly decrease the risk of age-associated mortality in old mice.

We next queried whether the reduced death rate in aged animals came at a cost of increased late-life morbidity. We measured physical function in experimental mice treated with PCC1 or vehicle monthly until death. Despite the longer remaining lifespan in PCC1-treated mice, physical function in the last 2 months of life was not significantly lower than that in vehicle-treated mice (Fig. 8n). Upon autopsy, the incidence of several age-related pathologies, tumour burden and cause of death were not significantly different between PCC1-treated and vehicle-treated mice (Fig. 8o and Extended Data Fig. 9a,b). However, expression of the SASP was reduced in solid organs, which was largely compatible with the decline of circulating levels of interleukin (IL)-6, colony-stimulating factor (CSF)2 and monocyte chemoattractant protein (MCP)1, representative SASP markers in peripheral blood (Extended Data Fig. 9c–f). We also observed decreased expression of the SASP in CD3<sup>+</sup> T cells in peripheral blood (Extended Data Fig. 9g), a cell lineage that exhibits a robust increase in p16<sup>INK4a</sup> expression during human ageing<sup>54</sup>. Furthermore, PCC1 treatment reduced oxidative stress in liver tissues, as evidenced by a decrease in adducts of the lipid peroxidation product 4-hydroxynonenal (HNE) and an increase in the ratio of reduced to oxidized glutathione (Extended Data Fig. 9h,i), consistent with the general properties of flavonoids, which exert antioxidant activity by counteracting free radicals and engaging the antioxidant defence system<sup>55,56</sup>.

In sum, the senolytic agent PCC1, a phytochemical component derived from GSE (or alternatively, at lower abundance, from natural products such as extracts of cinnamon, cacao, apple peels and

**Fig. 6 | PCC1-mediated senolysis prevents physical dysfunction and alleviates pathological symptoms.** **a**, Schematic of experimental procedures for cell transplantation and physical function tests in 5-month-old C57BL/6J male mice. **b**, Representative images showing *in vivo* luciferase activity 2 d after the last treatment of mice. Scale bars, 20 mm. **c**, Luminescence of transplanted cells as a percentage relative to the average signals in vehicle-treated animals. **d–f**, Measurement of maximal walking speed (relative to baseline) (**d**), hanging endurance (**e**) and grip strength (**f**) in 5-month-old C57BL/6J male mice, with tests performed 1 month after the last treatment. **g**, Schematic of the experimental design for transplantation and physical function measurements. **h–j**, Measurement of maximal walking speed (relative to baseline) (**h**), hanging endurance (**i**) and grip strength (**j**) in 28-week-old C57BL/6J male mice (2 weeks after the last treatment). **k**, One-year survival curves of 17-month-old animals implanted with  $0.5 \times 10^6$  control MEF cells and treated with vehicle (CTRL-vehicle) and mice implanted with  $0.5 \times 10^6$  senescent MEF cells treated either with vehicle (SEN-vehicle) or PCC1 (SEN-PCC1). Red arrowheads, cell implantation (on the 528th day of age) or the end of survival measurement (890th day of age).  $P$  values were calculated by two-sided log-rank (Mantel-Cox) tests. **l**, Comparative quantification of disease burden (left) and tumour burden (right) (shown as median with interquartile range) after implantation of senescent cells and treatment with vehicle or PCC1. **m**, Cause of death in animals that received implanted cells and were treated with vehicle or PCC1. For **d–f, h–j**, data are shown as box-and-whisker plots, in which boxes extend from the 25th to the 75th percentile with the median shown as a line in the middle, and whiskers indicate smallest and largest values. For **c–f, h–j**,  $P$  values were calculated by two-sided  $t$ -tests. Number of animals,  $n = 5$  per group for **c**,  $n = 10$  per group for **d–j**,  $n = 27$  for **k** and  $n = 13$  for **l, m**. NS,  $P > 0.05$ ; \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ .





modality holds prominent potential to remarkably delay age-related dysfunction, reduce age-related diseases and enhance health conditions, thus providing a new avenue to improve healthspan and lifespan in future geriatric medicine.

## Discussion

Ageing is an essentially inevitable process that progressively causes functional decline in nearly all organisms. Cellular senescence, a state of permanent growth arrest, has recently emerged as both a hallmark and a driver of ageing<sup>3,57</sup>. Senescent cells accumulate in aged tissues over time and contribute to an increasing list of pathologies<sup>58</sup>. Clearance of senescent cells from progeroid or naturally aged mice extends healthspan, increases lifespan and restrains age-related disorders including but not limited to atherosclerosis, osteoarthritis and neurodegenerative diseases<sup>59–62</sup>. Recent advances in age-related studies prompted a search for drugs that can selectively target senescent cells, particularly a new class of geroprotective agents termed senolytics or, less aggressively, senomorphics. To date, a handful of senolytics have been reported, including dasatinib and quercetin, fisetin, piperlongumine, heat-shock protein (HSP)90 inhibitors and BCL-2 family inhibitors such as ABT-263 (navitoclax) and ABT-737 (refs. <sup>11–13,18,19,21,22</sup>). Among them, BCL-2 inhibitors are the most widely used senolytics, although originally developed as therapies for lymphoma. ABT-737 targets BCL-2, BCL-xL and BCL-w but with low solubility and oral bioavailability. More effective for *in vivo* use, ABT-263 mainly inhibits BCL-2 and BCL-xL, whereas it frequently causes thrombocytopenia. Given the marked side effects of some senolytic compounds, there is a need to identify new compounds with senolytic activity but reduced cytotoxicity. In this study, we screened a PDMA-based drug library composed mainly of natural products with an aim to identify new agent(s) that can widely target senescent cells with optimal *in vivo* efficacy and safety. As a result, we identified PCC1, a phytochemical agent derived from natural sources, as a broad-spectrum senolytic compound. As a special advantage, PCC1 can alternatively act as a senomorphic agent to minimize SASP expression when used at low concentrations. Such an advantageous feature of PCC1 indeed largely resembles that of GSE, which can generate both senomorphic and senolytic effects.

Genetic and pharmacological strategies demonstrated an array of benefits of eliminating senescent cells to delay ageing and control diseases. Cellular senescence can be triggered by a variety of stimuli ranging from oncogenic activation, genotoxic stress, to inflammatory response and replicative exhaustion. Several compounds are identified as broad-spectrum senolytics, while others are selective against only a certain type of senescent cell. Differences in specificity imply individual choices of senolytics, which mainly depend on their intended clinical use. A recent study revealed ouabain, a natural compound belonging to the cardiac glycoside family, as a senolytic agent that can be used for both senescent cell elimination and cancer therapy, the latter implemented through a dual mechanism of action<sup>63</sup>. In this work, we discovered PCC1 as another new, natural and potent senolytic, which selectively and specifically induces

apoptosis of senescent cells but with limited cytotoxicity to proliferating cells<sup>64</sup>. Of note, at lower concentrations, PCC1 inhibits SASP expression, a property shared by some plant-derived flavonoids such as apigenin and kaempferol, which can act as senomorphics to limit the impact of senescent cells on age-related conditions<sup>65,66</sup>. Although few studies have disclosed such a dual mechanism of natural agents in targeting senescent cells, the recently synthesized quercetin surface functionalized Fe<sub>3</sub>O<sub>4</sub> nanoparticles exhibited both senolytic and senomorphic potential in human fibroblasts by enhancing AMP-activated protein kinase (AMPK) activity<sup>67</sup>.


The mechanism by which PCC1 achieves senolytic effects appears complex and requires further study. Our data suggest that PCC1 impairs the functional integrity of mitochondria, compromising  $\Delta\psi_m$ , leading to increased production of free radicals such as ROS and causing cytochrome c release in senescent cells but not in proliferating cells. A possible reason for this specificity is that senescent cells tend to develop a depolarized plasma membrane and have increased concentrations of H<sup>+</sup> (ref. <sup>64</sup>), a feature that might make them more susceptible to the action of PCC1. Of note, these alterations are accompanied by upregulated expression of pro-apoptotic factors, specifically NOXA and PUMA, events that also critically promote senescent cell apoptosis. Within the family of procyanidins, members of which are known to derive from the polymerisation of flavan-3-ol molecules and exist as oligomers or polymers<sup>28</sup>, PCC1 seems to be functionally unique. Our experimental data imply a noticeable difference between PCC1 (a trimer) and other procyanidins (most of which are indeed monomers or dimers, such as PCB2). Since we did not comprehensively assay procyanidin family members, whether the number of monomers in the molecule determines its anti-senescence potential remains an open but intriguing question, and the underlying mechanisms deserve continued studies in the future.


Cellular senescence per se is a highly heterogeneous process that depends on different cell origins and environmental stimuli<sup>68</sup>. One of the key features of PCC1 is its ability to efficiently clear senescent cells in a wide spectrum of cell types and stressors, including replication, oncogenes, irradiation and chemotherapy. In this study, we compared PCC1 with other reported senolytics for effects on human stromal cells, fibroblasts, HUVECs and MSCs, major cell types in the tissue microenvironment. As reported, ABT-263 eliminates senescent human embryonic fibroblasts (HEFs) and HUVECs but has little effect on human pre-adipocytes<sup>12,18</sup>. The combined use of dasatinib and quercetin can deplete all three types of senescent cells in a dose-dependent manner but is toxic to proliferating cells<sup>11,69,70</sup>. Fisetin, another natural flavonoid reported as a senolytic agent, displays modest effects on senescent HEFs and pre-adipocytes only at high concentrations<sup>20,21</sup>. By contrast, PCC1 has the potential to overcome these limitations, including cell type dependency, high toxicity in nonsenescent cells and low efficiency against senescent cells. Although, when used alone, quercetin (another flavonoid in GSE) per se displayed cytotoxicity against senescent stromal cells, its efficacy is generally lower than that of PCC1 (compare Fig. 2a,c and Supplementary Figs. 3n and 4n). Together, PCC1 has a superior senolytic activity with high specificity and efficiency for a wider

**Fig. 7 | PCC1 treatment alleviates physical dysfunction of animals exposed to WBI.** **a**, Schematic of the experimental procedure for mice experiencing WBI and physical function tests. **b**, Whole-body snapshot comparison of C57BL/6J male mice that were naive, exposed to WBI followed by vehicle treatment or exposed to WBI and treated with PCC1, respectively. **c**, An in-cage picture of animals described in **a** under preclinical conditions. **d**, Representative images of SA- $\beta$ -Gal staining of cardiac tissue of untreated (naive) and WBI-treated mice subjected to vehicle or PCC1 treatment. Scale bar, 200  $\mu$ m. **e**, Representative images of SA- $\beta$ -Gal staining of pulmonary tissue of mice as described in **d**. Scale bar, 200  $\mu$ m. **f**, Comparative statistics of SA- $\beta$ -Gal staining of cardiac tissue of animals examined in **d**. **g**, Comparative statistics of SA- $\beta$ -Gal staining of pulmonary tissue of animals examined in **e**. **h**, Quantitative measurement of SASP expression at the transcription level in tissues collected from animals treated under conditions described in **a**. **ij**, Measurement of running distance on the treadmill (**i**) and grip strength (**j**) of experimental mice. For **f–j**, *P* values were calculated by two-sided *t*-tests. **k**, Kaplan–Meier survival analysis of C57BL/6J mice exposed to WBI and treated weekly with vehicle or PCC1, with naive mice as the untreated control. CI, confidence interval; HR, hazard ratio; DFI, disease-free interval. *P* values were calculated by two-sided log-rank (Mantel–Cox) tests. Data in bar graphs are shown as mean  $\pm$  s.d. and are representative of three independent experiments. NS, *P* > 0.05; \**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001; \*\*\*\**P* < 0.0001.

range of cell types than many reported senolytics such as ABT-263, dasatinib, quercetin and fisetin and can target senescent cells generated by several major types of senescence inducers.

We found that PCC1 exerts apoptosis-inducing effect on senescent cells under in vivo conditions. PCC1 eliminated therapy-induced senescent cells effectively and reduced senescence





markers in solid organs, highlighting its effectiveness in vivo. In this study, we also treated naturally aged mice with PCC1 and tested its effects on senescent cells, chronic inflammation and

physical function. First, PCC1 treatment depleted senescent cells in multiple tissues and decreased SASP-associated signatures as shown by GSEA analysis. Second, PCC1 could suppress expression



**Fig. 8 | Intermittent PCC1 administration extends both healthspan and lifespan of aged mice.** **a**, Schematic design for physical examination of 20-month-old C57BL/6J male mice treated with PCC1 once every 2 weeks (biweekly) for 4 months. **b**, Representative images of SA- $\beta$ -Gal staining of kidneys from young and aged mice treated with vehicle or PCC1. Scale bar, 200  $\mu$ m. **c**, Quantification of SA- $\beta$ -Gal staining as described in **b**. Data represent mean  $\pm$  s.d. **d–h**, Quantification of maximal walking speed (relative to baseline) (**d**), hanging endurance (**e**), grip strength (**f**), treadmill endurance (**g**) and daily activity (**h**) of 20-month-old C57BL/6J male mice after the 4-month treatment. **i**, Quantification of the time needed to cross the balance beam. Data points before and after treatment of each animal are connected to allow direct comparison of treatment effects. **j**, Quantitative transcript profiling of SASP expression in lung tissues collected from 6-month-old untreated (6M), 24-month-old vehicle-treated (24M-vehicle) and 24-month-old PCC1-treated mice (24M-PCC1). Data are shown as mean  $\pm$  s.d. and were derived from three biological replicates ( $n = 3$  independent assays). **k**, Schematic design for lifespan analyses of mice (both sexes) at 24–27 months of age. **l,m**, Post-treatment survival (**l**) and whole-life survival (**m**) curves of C57BL/6J animals treated biweekly with PCC1 ( $n = 91$ ; 48 males, 43 females) or vehicle ( $n = 80$ ; 42 males, 38 females) starting at 24–27 months of age. **n**, Maximal walking speed and hanging endurance averaged over the last 2 months of life ( $n = 10$  mice per group) and lifespan for the longest-living mice (top 20) in both groups. **o**, Disease burden and tumour burden at death. For both sexes,  $n = 60$  mice per arm. For males,  $n = 31$  for PCC1 and  $n = 33$  for vehicle. For females,  $n = 29$  for PCC1 and  $n = 27$  for vehicle. For **c–h,j**,  $n = 3$  biologically independent assays. Data are displayed as box-and-whisker plots, in which a box extends from the 25th to the 75th percentile with the median shown as a line in the middle, and whiskers indicate smallest and largest values (**d–h,n**) or as mean  $\pm$  s.d. (**o**). Unpaired two-tailed *t*-tests (**c–j,n,o**) and Cox proportional-hazard regression models (**l,m**) were used to determine statistical significance.

of SASP-associated genes in aged livers and kidneys and reduce chronic low-grade inflammation in the blood. Third, PCC1 alleviated impaired motor function, balance, exhausted exercise, muscle strength and spontaneous exploration in aged mice. Most importantly, performance on RotaRod and beam balance testing in the PCC1-treated group was improved compared with that in the initial pretreatment condition. Collectively, the phytochemical compound PCC1 selectively targets senescent cells in the tissue microenvironment and generates remarkable biological effects in naturally aged mice.

Similar to chemically synthesized counterparts, naturally derived procyanidins manifest anti-inflammatory, anti-arthritic, anti-allergic and anticancer activities, scavenge oxygen free radicals and suppress radiation-induced peroxidation activity<sup>36,71</sup>. As an epicatechin trimer isolated from plant material, most prominently from grape seeds, PCC1 was shown to provide health benefits in chronic pathological conditions<sup>72</sup>. However, thorough evaluation of the toxicological effects of PCC1 *in vivo* is crucial for a potential clinical application. Our data showed that high-concentration (20 mg per kg) and high-frequency PCC1 (biweekly) treatment had no apparent systemic toxicities. In summary, our study demonstrates the superiority and relative safety of a geroprotective strategy that selectively targets senescent cells in aged or treatment-damaged tissues across a broad spectrum of cell types. However, it is possible that PCC1 concentrations *in vivo* vary between organs and depend on the administered dose, pharmacodynamics and pharmacokinetics and that local concentrations are not high enough to achieve a senolytic effect in some tissue types. In this case, it seems likely that a combination of both senolytic and senomorphic effects underlies the outcomes that we observed *in vivo*.

Altogether, our study opens a new avenue for extending healthspan and prolonging lifespan and treating age-related pathologies with a senotherapeutic agent (with both senomorphic and senolytic potential), which is derived from natural sources and possesses pronounced efficacy. The potential anti-ageing effects of PCC1 demonstrated in our preclinical assays provide good support for further translational and clinical development of PCC1, with the overall aim of achieving a longer and healthier life.

## Methods

**Preclinical animal studies.** All procedures with experimental animals were approved by the Institutional Animal Care and Use Committee (IACUC) at Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, with all animals handled in accordance with the guidelines for animal experiments defined by the institutional IACUC.

**Cell lines, *in vitro* culture and lentiviruses.** The human primary prostate stromal cell line PSC27 was kindly provided by P. Nelson (Fred Hutchinson Cancer Research Center) and cultured in PSC complete medium (80% MCDB131

(Thermo Fisher Scientific) supplemented with 10% FCS, nonessential amino acids, insulin, dexamethasone, transferrin, selenium and 20% AmnioMAX (Thermo Fisher Scientific) as described previously<sup>15</sup>. The human foetal lung fibroblast cell line WI38 and the HUVEC line were purchased from ATCC (CCL-75 and PCS-100-010, respectively) and maintained in DMEM and F-12K medium, respectively, as recommended by the provider. The MSC line was derived from human umbilical vein tissues and cultured in MSC complete medium with 10  $\mu$ g ml<sup>-1</sup> recombinant human insulin as reported<sup>73</sup>. All cell lines tested negative for microbial contamination and were routinely authenticated with STR assays.

Lentiviral particles were produced using Lipofectamine 2000 and a packaging kit (Thermal Scientific) based on the manufacturer's instructions. PSC27 cells infected with viruses with the puromycin resistance gene were selected using puromycin (1  $\mu$ g ml<sup>-1</sup>) for 3 d.

**Cell treatment and analyses.** Stromal cells were grown until 60–80% confluent (control) and treated with bleomycin (50  $\mu$ g ml<sup>-1</sup>, MedChemExpress) for 12 h. After treatment, cells were rinsed twice with PBS and maintained for 7–10 d in medium. Alternatively, cells were passaged consecutively to induce replicative exhaustion as RS or lentivirally infected with a construct encoding full length HRAS<sup>G12V</sup> and selected with puromycin (1  $\mu$ g ml<sup>-1</sup>) for 3 d and maintained for 7 d until senescence (OIS).

DNA damage was evaluated by immunostaining for  $\gamma$ H2AX or p53-BP1 foci following a four-category counting strategy as previously reported<sup>15</sup>. Random fields were chosen to quantify DDR foci using CellProfiler (<http://www.cellprofiler.org>). For experiments with specific needs, HS-1793 (TargetMol), CCCP (TargetMol) and ruxotemide (LTX325) (Selleckchem) were used at concentrations of 10  $\mu$ M, 10  $\mu$ M and 50  $\mu$ g ml<sup>-1</sup>, respectively. For clonogenic assays, cells were seeded at  $1 \times 10^3$  cells per dish in 10-mm dishes for 24 h before being treated with chemicals. Cells were fixed in 2% paraformaldehyde 7–10 d after treatment, gently washed with PBS and stained instantly with 10% crystal violet in 50% methanol. Excess dye was removed with PBS, and plates were photographed. Colony formation was quantified by counting single colonies per dish.

**Cell viability assays.** Senescent or control cells were seeded into wells of a 96-well plate before being treated with vehicle (0.1% DMSO or PBS) or natural product library agents (listed in Supplementary Table 5) with 5,000 cells per well at three concentrations (1, 5 and 10  $\mu$ g ml<sup>-1</sup> for agents of unknown molecular weight; or 1, 5 and 10  $\mu$ M for agents of known molecular weight) for three consecutive days. Cultures were digested with 0.25% trypsin and 1 mM EDTA and collected in PBS containing 2% FBS, with survival measured by a cell-based MTS assay (Promega). The top candidate agents were further screened in a 30-d treatment at additional concentrations. MSCs (P5–P10) were seeded into six-well plates at a density of 30,000 cells per well. Culture medium with the different candidate agents was changed every other day. PD potential was quantified by determining the relative proliferative capacities of MSCs treated with agents of senotherapeutic capacity, and cells with potential to recover after withdrawal of bleomycin from the medium were allowed to expand for PD measurement.

Apoptosis was assessed using an annexin V-FITC cell apoptosis assay kit (Beyotime). Briefly, cells were sequentially incubated with annexin V-FITC and PI before being sorted using a Beckman flow cytometer (Beckman, CytoFLEX LX). Viable cells (PI<sup>-</sup> cells) were analysed at a constant flow rate and calculated as a percentage of control cells treated with vehicle using the following formula: percentage of control =  $(N_{drug} N_c^{-1}) \times 100$ , where  $N_{drug}$  and  $N_c$  represent the absolute number of PI<sup>-</sup> viable drug-treated or vehicle-treated cells, respectively. Dose–response curves were constructed for each tested agent, and half-maximal inhibitory concentrations were calculated using probit analysis<sup>74</sup>.

**Radiation of animals.** Animals were housed in a specific pathogen-free animal facility at an ambient temperature of 22–25 °C with 50% humidity, under a 12-h light–dark cycle, with free access to food and were fed ad libitum. For induction of *in vivo* senescence, C57BL/6J mice (males, Nanjing Model Animal Center) at 8–12 weeks of age were exposed to a sublethal dose (5 Gy) of WBI. Eight weeks later, animals were injected with 20 mg per kg PCC1 *i.p.* or vehicle once per week for four consecutive weeks. Mice were killed 24 h after the last injection. Mouse tissues were collected for RNA extraction, paraffin embedded for immunohistology or frozen in OCT solution for cryosectioning and SA- $\beta$ -Gal staining. Mice used for all experiments were randomly assigned to control or treatment groups. Both sexes were used throughout the study.

The experimental procedure for animal radiation was approved by the IACUC at Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, with all animals handled in accordance with the guidelines for animal experiments defined by the institutional IACUC.

**Chemotherapeutic regimens.** NOD–SCID mice (males, Nanjing Model Animal Center) at 6–8 weeks of age were housed and maintained in accordance with the animal guidelines of Shanghai Institutes for Biological Sciences. For establishment of mouse tumour xenografts, human prostate stromal cells (PSC27 cells) and cancer epithelial cells (PC3 or PC3–Luc) were mixed at a ratio of 1:4, with each *in vitro* recombinant comprising  $1.25 \times 10^6$  total cells before subcutaneous implantation as described previously<sup>14,47</sup>. Two weeks later, mice were randomized into groups and subjected to preclinical treatments. Animals were treated with MIT (0.2 mg per kg) alone, PCC1 (20 mg per kg) alone or MIT with PCC1. MIT was delivered via *i.p.* injection biweekly starting from the beginning of the 3rd week, with a total of three 2-week cycles throughout the whole regimen as reported previously<sup>16,17</sup>. PCC1 was delivered via *i.p.* injection 2 weeks after the first dose of MIT and then given biweekly, with a total number of two doses throughout the regimen.

Mice were killed at the end of the 8th week after tumour xenografting. Primary tumours were measured once biweekly starting from the beginning of the 4th week and after animal dissection, and the approximate ellipsoid tumour volume ( $V$ ) was measured and calculated from the tumour length ( $l$ ) and width ( $w$ ) using the following formula:  $V = (\pi \times 6^{-1}) \times ((l + w) \times 2^{-1})^3$ . Excised tumours were either freshly snap-frozen or fixed in 10% buffered formalin and subsequently processed as formalin-fixed and paraffin-embedded sections for IHC staining. Animals were weighed weekly and checked for tumour growth semi-weekly. Bulky disease was considered present when the tumour burden was prominent at the hind flank (tumour volume  $\geq 2,000$  mm<sup>3</sup>). When at least five of the ten mice in a treatment group had developed bulky disease, the median survival duration for that group was considered to be reached. Throughout the regimen, tumours were not allowed to grow further if the maximal threshold was surpassed (any dimension  $\geq 15$  mm), and mice were immediately killed according to the animal care and use protocol.

Tumour growth and metastasis in mice were alternatively evaluated using bioluminescence emitted by PC3–Luc cells, which stably express firefly luciferase. A Xenogen IVIS Imager (Caliper Life Sciences) was used to document bioluminescence across the visible spectrum in isoflurane-anaesthetized animals, with the substrate D–luciferin (150 mg per kg, BioVision) injected subcutaneously and freshly each time for imaging-based tumour surveillance.

The chemotherapeutic procedure was approved by the IACUC at Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, with all animals treated in accordance with the guidelines for animal experiments defined by the institutional IACUC.

**Senescent cell clearance and lifespan studies.** For age-related studies, WT C57BL/6J male mice were maintained in a specific pathogen-free facility at 22–25 °C under a 12-h–12-h light–dark cycle (lights on from 08:00 to 20:00) with free access to food (standard mouse diet, LabDiet 5053) and water provided ad libitum. The experimental procedure was approved by the IACUC at Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, with all animals treated in accordance with the guidelines for animal experiments defined by the IACUC.

Mice were sorted by body weight from low to high, and pairs of mice were selected according to similar body weights. Either control cell or senescent cell transplant treatments were assigned to every other mouse using a random number generator, with the intervening mice assigned to the other treatment to allow mice transplanted with control and senescent cells to be matched by weight. After acclimation in the animal facility at Shanghai Institute of Nutrition and Health, mice aged 5 months were subcutaneously transplanted with MEFs ( $0.5 \times 10^6$  cells per side) and treated immediately with vehicle or PCC1 (prepared in ethanol–polyethylene glycol 400–Phosal 50 PG at 10:30:60, 20 mg per kg) for 1 week (*i.p.* injection once every 3 d) before bioluminescence imaging assays. Physical function tests were performed 1 month after bioluminescence imaging at the age of approximately 25 weeks. The first death occurred approximately 3 months after the last physical function test. For treatment-delayed mice that received cell transplantation, a first wave of physical function tests was conducted 5 weeks after cell transplantation. Animals were then subjected to treatment with vehicle for 5 d (for those with control cells as the first group) or vehicle or PCC1 for 5 d (for those with senescent cells, as the second and third groups, respectively) (*i.p.* injections were performed consecutively for each condition once every 5 d). Mice were

maintained for 2 weeks, after which the second wave of physical function assays was conducted. For mid-age studies, 17-month-old C57BL/6J mice were implanted with control or senescent MEF cells and underwent treatment with vehicle or PCC1. Administration was performed once biweekly, and animals were measured for survival within a 1-year time frame after cell implantation.

For senolytic studies of natural ageing, 20-month-old WT C57BL/6J mice (males) without transplantation were used and were sorted according to their body weight and randomly assigned to vehicle or PCC1 treatment. Animals were treated once every 2 weeks in an intermittent manner for 4 months before physical tests were performed at 24 months of age. For senolytic trials pertaining to lifespan extension at advanced age, we used animals at a very old age. Starting at 24–27 months of age (equivalent to a human age of 75–90 years), mice (both sexes) were treated once every 2 weeks (biweekly) with vehicle or PCC1 by oral gavage (20 mg per kg) for three consecutive days. Some mice were moved from their original cages during the study to minimize single cage-housing stress. In each case, RotaRod (TSE Systems) and hanging tests were chosen for monthly measurement of maximal speed and hanging endurance, respectively, as these tests are considered sensitive and noninvasive. Mice were euthanized and scored as having died if they exhibited more than one of the following signs: (1) unable to drink or eat, (2) reluctant to move even with stimulus, (3) rapid weight loss, (4) severe balance disorder or (5) bleeding or ulcerated tumour. No mouse was lost due to fighting, accidental death or dermatitis. The Cox proportional-hazard model was used for survival analyses.

**Postmortem pathological examination.** Animal cages were checked every day, and dead mice were removed from cages. Within 24 h, corpses were opened (abdominal cavity, thoracic cavity and skull) and preserved in 4% paraformaldehyde individually for at least 7 d, and decomposed or disrupted bodies were excluded. Preserved bodies were given to pathologists for blinded examination, following an assessment routine. Briefly, tumour burden (sum of different types of tumours in each mouse), disease burden (sum of different histopathological changes in major organs in each mouse), severity of each lesion and inflammation (lymphocytic infiltrate) were evaluated.

**Bioluminescence imaging.** Experimental mice were injected *i.p.* with 3 mg D–luciferin (potassium salt, BioVision) in 200  $\mu$ l PBS. Mice were anaesthetized by inhalation of isoflurane, and bioluminescence images were acquired using a Xenogen IVIS 200 System (Caliper Life Sciences) according to the manufacturer's instructions.

**Physical function assessments.** All physical tests were performed at least 5 d after the last dose of senolytic treatment. Maximal walking speed was measured using an accelerating RotaRod system (TSE Systems). Mice were trained on the RotaRod for 3 d at speeds of 4, 6 and 8 r.p.m. for 200 s on days 1, 2 and 3. On the test day, mice were placed onto the RotaRod, which was started at 4 r.p.m. The rotating speed was accelerated from 4 to 40 r.p.m. over a 5-min interval. The speed was recorded when the mouse dropped off the RotaRod, with results averaged from three or four trials and normalized to the baseline speed. Training was not repeated for mice that had been trained within the preceding 2 months. Forelimb grip strength (N) was determined using a Grip Strength Meter (Columbus Instruments), with results averaged over ten trials. To measure grip strength, the mouse is swung gently by the tail so that its forelimbs contact the bar. The mouse instinctively grips the bar and is pulled horizontally backwards, exerting tension. When the tension becomes too great, the mouse releases the bar. For the hanging test, mice were placed onto a metal wire (2 mm thick) that was 35 cm above a padded surface, while animals were allowed to grab the wire with their forelimbs only. Hanging time was normalized to body weight as hanging duration (s)  $\times$  body weight (g), with results averaged from two or three trials for each mouse. A Comprehensive Laboratory Animal Monitoring System (CLAMS, Columbus Instruments) was used to monitor daily activity and food intake over a 24-h period (12 h of light and 12 h of dark). The CLAMS system was equipped with an OxyMax Open Circuit Calorimeter System (Columbus Instruments). For treadmill performance, mice were acclimated to a motorized treadmill at an incline of 5° (Columbus Instruments) over 3 d for 5 min each day, starting at a speed of 5 m min<sup>-1</sup> for 2 min and progressing to 7 m min<sup>-1</sup> for 2 min and then 9 m min<sup>-1</sup> for 1 min. On the test day, mice ran on the treadmill at an initial speed of 5 m min<sup>-1</sup> for 2 min, and then the speed was increased by 2 m min<sup>-1</sup> every 2 min until the mice were exhausted. The speed at which the mouse dropped from the RotaRod was recorded, and results were averaged from three trials. Exhaustion was defined as the inability to return onto the treadmill despite a mild electrical shock stimulus and mechanical prodding. Distance was recorded, and total work (kJ) was calculated using the following formula: mass (kg)  $\times$  g (9.8 m s<sup>-2</sup>)  $\times$  distance (m)  $\times$  sin (5°).

**Comprehensive laboratory animal-monitoring system.** In a subset of 8–10 mice per group, habitual ambulatory, rearing and total activity, oxygen consumption (VO<sub>2</sub>) and carbon dioxide production (VCO<sub>2</sub>) of individual mice were monitored over a 24-h period (12 h of light and 12 h of dark) using a CLAMS equipped with an OxyMax Open Circuit Calorimeter System (Columbus Instruments). Ambulatory, rearing and total activities were summed and analysed for light and



dark periods under fed conditions.  $VO_2$  and  $VCO_2$  values were used to calculate the respiratory exchange ratio and  $VO_2$ . Respiratory exchange ratio values were used to determine the basal metabolic rate (in  $\text{kcal h}^{-1}$  per kg).

**SA- $\beta$ -Gal assay of tissue and histological evaluation.** For SA- $\beta$ -Gal staining, frozen sections were dried at  $37^\circ\text{C}$  for 20–30 min before being fixed for 15 min at room temperature. Frozen sections were washed three times with PBS and incubated with SA- $\beta$ -Gal staining solution (Beyotime) overnight at  $37^\circ\text{C}$ . After completion of SA- $\beta$ -Gal staining, sections were stained with eosin for 1–2 min, rinsed under running water for 1 min, differentiated in 1% acid alcohol for 10–20 s and washed again under running water for 1 min. Sections were dehydrated in increasing concentrations of alcohol and cleared in xylene. After drying, samples were examined under a bright-field microscope.

Frozen prostate, lung, liver and kidney sections stained with SA- $\beta$ -Gal were quantified using ImageJ software (NIH) to measure the SA- $\beta$ -Gal<sup>+</sup> area. The total area was quantified by the eosin-positive area, while relative quantities of SA- $\beta$ -Gal<sup>+</sup> cells were calculated using the SA- $\beta$ -Gal<sup>+</sup> area divided by the total area. For statistics of the SA- $\beta$ -Gal<sup>+</sup> area of the lung, regions of the lung were randomly selected to be photographed, avoiding analysis of larger pulmonary blood vessels and the trachea. For statistical analysis of the SA- $\beta$ -Gal-positive area of the liver, regions were randomly selected to be photographed. For statistical analysis of the SA- $\beta$ -Gal<sup>+</sup> area of the kidney, regions of the renal cortex were randomly selected to be photographed. Each tissue was measured over 10–18 regions.

For endogenous acidic  $\beta$ -galactosidase ( $\beta$ -Gal) staining, frozen kidney and salivary gland sections were dried at  $37^\circ\text{C}$  for 20–30 min and then fixed in  $\beta$ -Gal staining fixative solution for 15 min at room temperature. Frozen sections were washed three times with PBS and incubated with  $\beta$ -Gal staining solution (Beyotime) overnight at  $37^\circ\text{C}$ . Subsequent steps were similar to those of the regular SA- $\beta$ -Gal staining protocol.

For IHC assays, formalin-fixed paraffin-embedded tissue blocks were cut into sections ( $7\ \mu\text{m}$  thick), which were subjected to deparaffinisation and hydration. Antigen was retrieved in citrate buffer (0.01 M, pH 6.0) at  $95^\circ\text{C}$  for 10 min, and sections were treated with blocking buffer (goat serum, 1:60 in 0.1% BSA in PBS) for 60 min at room temperature. Samples were further incubated with Avidin–Biotin (Vector Laboratories) for 15 min at room temperature. Sections were stained with primary antibody at  $4^\circ\text{C}$  overnight before being incubated with biotinylated secondary antibody (Vector Laboratories) for 30 min. Finally, fluorescein-labelled avidin DCS (Vector Laboratories) was applied for 20 min. IHC staining was performed by a pathologist using a BOND RX Fully Automated Research Stainer (Leica). Slides were retrieved for 20 min using Epitope Retrieval Solution 1 (citrate, Leica) and incubated in Protein Block (Dako) for 5 min. Primary antibodies were diluted in Background Reducing Diluent (Dako) as follows: anti-p16<sup>INK4A</sup> (rabbit, monoclonal, Abcam, ab108349) at 1:600, anti-cleaved caspase 3 (rabbit, polyclonal, Cell Signaling, 9661L) at 1:200 and anti-F4/80 (rat, monoclonal, Abcam, ab90247) at 1:500, except for anti-CD68 antibody (mouse, monoclonal, Dako, M0876), which was diluted in Bond Diluent (Leica) at 1:200. All primary antibodies were diluted in Background Reducing Diluent (Dako) and incubated for 15 min, and the Polymer Refine Detection System (Leica) was used. This system includes a hydrogen peroxidase block, Post Primary and Polymer Reagent, DAB and haematoxylin steps. Visualisation of immunostaining was achieved by incubating the slides for 10 min in DAB and DAB buffer (1:19 mixture) from the Bond Polymer Refine Detection System. Slides were counterstained for 5 min with Schmidt haematoxylin, followed by several rinses with  $1\times$  Bond wash buffer and distilled water. Slides were subsequently dehydrated with increasing concentrations of ethanol and cleared with xylene before being mounted in xylene-based VECTASHIELD medium (Vector Laboratories). Imaging was performed with an LSM 780 Zeiss confocal microscope.

**In vivo cytotoxicity assessment using blood tests.** For routine blood examination, 100  $\mu\text{l}$  fresh blood was acquired from each animal and mixed with EDTA immediately. Blood samples were analysed with Celltac Alpha MEK-6400 series haematology analysers (Nihon Kohden). For serum biochemical analyses, blood samples were collected and clotted for 2 h at room temperature or overnight at  $4^\circ\text{C}$ . Samples were then centrifuged (1,000g, 10 min) to obtain serum. An aliquot of approximately 50  $\mu\text{l}$  serum was subjected to analysis for creatinine, urea, alkaline phosphatase and alanine transaminase with the Chemistry Analyser (Mindray). Circulating levels of haemoglobin, white blood cells, lymphocytes and platelets were evaluated using dry-slide technology on a VetTest 8008 chemistry analyser (IDEXX) as reported previously<sup>47</sup>.

All animal experiments were conducted in compliance with the NIH Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011) and the ARRIVE guidelines and were approved by the IACUC of Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences. For each preclinical regimen, animals were monitored for conditions including hypersensitivity (changes in body temperature, altered breathing and ruffled fur), body weight, mortality and changes in behaviour (that is, loss of appetite and distress) and were disposed of appropriately according to the individual pathological severity as defined by relevant guidelines.

**Measurement of lipid peroxidation.** Levels of HNE–protein adducts in liver lysates prepared in RIPA buffer were measured in livers of mice using the OxiSelect HNE Adduct Competitive ELISA kit (Cell Biolabs) as formerly described<sup>75</sup>.

**Examination of glutathione levels.** Mouse livers fixed in 5% sulfosalicylic acid were prepared and analysed to determine the concentration of reduced (GSH) and oxidized (GSSG) glutathione using the Glutathione Assay kit (Cayman Chemical) as previously described<sup>75</sup>. Sample absorbance was measured at a wavelength of 405 nm using a plate reader, and the ratio of GSH:GSSG was obtained for each tested tissue sample.

**Statistical analysis.** Unless otherwise specified, data in figures are presented as mean  $\pm$  s.d., and statistical significance was determined by unpaired two-tailed Student's *t*-test (comparing two groups), one-way ANOVA or two-way ANOVA (comparing more than two groups with Tukey's post hoc comparison), Pearson's correlation coefficient test, Kruskal–Wallis log-rank test, Wilcoxon–Mann–Whitney test or Fisher's exact test with GraphPad Prism 8.3 primed with customized parameters. Cox proportional hazards regression model and multivariate Cox proportional hazards model analyses were performed with SPSS software. Investigators were blinded to allocation during most experiments and outcome assessments. We used baseline body weight to assign mice to experimental groups to achieve similar body weights between groups, so that only randomisation within groups matched by body weight was conducted.

To determine sample size, we set the values of type 1 error ( $\alpha$ ) and power ( $1 - \beta$ ) to be statistically adequate: 0.05 and 0.80, respectively<sup>76</sup>. We then determined *n* on the basis of the smallest effect that we measured. If the required sample size was too large, we chose to reassess the objectives or to more tightly control experimental conditions to reduce variance. For all statistical tests, *P* values  $< 0.05$  were considered significant, with *P* values presented as follows throughout the article: NS,  $P > 0.05$ ; \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ .

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

Source data are provided with this paper. Data that support the plots in this paper and other findings of this study are available from the corresponding author upon reasonable request. RNA-seq data generated in the present study were deposited in the Gene Expression Omnibus database under accession codes GSE156301, GSE164012 and GSE178376, respectively.

Received: 14 April 2021; Accepted: 13 October 2021;

Published online: 6 December 2021

## References

- Khosla, S., Farr, J. N., Tchkonina, T. & Kirkland, J. L. The role of cellular senescence in ageing and endocrine disease. *Nat. Rev. Endocrinol.* **16**, 263–275 (2020).
- Rocca, W. A. et al. Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. *Mayo Clin. Proc.* **89**, 1336–1349 (2014).
- Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. *Cell* **153**, 1194–1217 (2013).
- Pignolo, R. J., Passos, J. F., Khosla, S., Tchkonina, T. & Kirkland, J. L. Reducing senescent cell burden in aging and disease. *Trends Mol. Med.* **26**, 630–638 (2020).
- Gorgoulis, V. et al. Cellular senescence: defining a path forward. *Cell* **179**, 813–827 (2019).
- Baker, D. J. et al. Naturally occurring p16<sup>INK4a</sup>-positive cells shorten healthy lifespan. *Nature* **530**, 184–189 (2016).
- Baker, D. J. et al. Clearance of p16<sup>INK4a</sup>-positive senescent cells delays ageing-associated disorders. *Nature* **479**, 232–236 (2011).
- Tchkonina, T. & Kirkland, J. L. Aging, cell senescence, and chronic disease: emerging therapeutic strategies. *JAMA* **320**, 1319–1320 (2018).
- Hickson, L. J. et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. *EBioMedicine* **47**, 446–456 (2019).
- Justice, J. N. et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. *EBioMedicine* **40**, 554–563 (2019).
- Zhu, Y. et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. *Aging Cell* **14**, 644–658 (2015).
- Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. *Aging Cell* **15**, 428–435 (2016).
- Fuhrmann-Stroissnigg, H. et al. Identification of HSP90 inhibitors as a novel class of senolytics. *Nat. Commun.* **8**, 422 (2017).
- Zhang, B. Y. et al. The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. *Nat. Commun.* **9**, 1723 (2018).

15. Sun, Y. et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. *Nat. Med.* **18**, 1359–1368 (2012).
16. Xu, Q. et al. Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression. *Aging Cell* **18**, e13027 (2019).
17. Han, L. et al. Senescent stromal cells promote cancer resistance through SIRT1 loss—potentiated overproduction of small extracellular vesicles. *Cancer Res.* **80**, 3383–3398 (2020).
18. Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat. Med.* **22**, 78–83 (2016).
19. Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. *Nat. Commun.* **7**, 11190 (2016).
20. Yousefzadeh, M. J. et al. Fisetin is a senotherapeutic that extends health and lifespan. *EBioMedicine* **36**, 18–28 (2018).
21. Zhu, Y. et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. *Aging* **9**, 955–963 (2017).
22. Wang, Y. Y. et al. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. *Aging* **8**, 2915–2926 (2016).
23. Li, W., He, Y., Zhang, R., Zheng, G. & Zhou, D. The curcumin analog EF24 is a novel senolytic agent. *Aging* **11**, 771–782 (2019).
24. Martel, J. et al. Emerging use of senolytics and senomorphics against aging and chronic diseases. *Med. Res. Rev.* **40**, 2114–2131 (2020).
25. Hernandez-Segura, A., Nehme, J. & Demaria, M. Hallmarks of cellular senescence. *Trends Cell Biol.* **28**, 436–453 (2018).
26. Chen, B. et al. Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of IκBα and blocking mitochondrial damage. *Arthritis Res. Ther.* **21**, 193 (2019).
27. Cadiz-Gurra, M. D. et al. Cocoa and grape seed byproducts as a source of antioxidant and anti-inflammatory proanthocyanidins. *Int. J. Mol. Sci.* **18**, 376 (2017).
28. Rigotti, M. et al. Grape seed proanthocyanidins prevent H<sub>2</sub>O<sub>2</sub>-induced mitochondrial dysfunction and apoptosis via SIRT 1 activation in embryonic kidney cells. *J. Food Biochem.* **44**, e13147 (2020).
29. Long, M. et al. The protective effect of grape-seed proanthocyanidin extract on oxidative damage induced by zearalenone in Kunming mice liver. *Int. J. Mol. Sci.* **17**, 808 (2016).
30. Chen, F. et al. Grape seed proanthocyanidin inhibits monocrotaline-induced pulmonary arterial hypertension via attenuating inflammation: in vivo and in vitro studies. *J. Nutr. Biochem.* **67**, 72–77 (2019).
31. Georgieva, E. et al. Mitochondrial dysfunction and redox imbalance as a diagnostic marker of 'free radical diseases'. *Anticancer Res.* **37**, 5373–5381 (2017).
32. Zhu, W., Li, M. C., Wang, F. R., Mackenzie, G. G. & Oteiza, P. I. The inhibitory effect of ECG and EGCG dimeric procyanidins on colorectal cancer cells growth is associated with their actions at lipid rafts and the inhibition of the epidermal growth factor receptor signaling. *Biochem. Pharmacol.* **175**, 113923 (2020).
33. Koteswari, L. L., Kumari, S., Kumar, A. B. & Malla, R. R. A comparative anticancer study on procyanidin C1 against receptor positive and receptor negative breast cancer. *Nat. Prod. Res.* **34**, 3267–3274 (2020).
34. Geng, L. et al. Chemical screen identifies a geroprotective role of quercetin in premature aging. *Protein Cell* **10**, 417–435 (2018).
35. Rodriguez, R. & Meuth, M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. *Mol. Biol. Cell* **17**, 402–412 (2006).
36. Zhao, J., Wang, J., Chen, Y. & Agarwal, R. Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation–promotion protocol and identification of procyanidin B5-3'-gallate as the most effective antioxidant constituent. *Carcinogenesis* **20**, 1737–1745 (1999).
37. Sun, P. et al. Trimer procyanidin oligomers contribute to the protective effects of cinnamon extracts on pancreatic beta-cells in vitro. *Acta Pharmacol. Sin.* **37**, 1083–1090 (2016).
38. Gao, W. et al. Procyanidin B1 promotes in vitro maturation of pig oocytes by reducing oxidative stress. *Mol. Reprod. Dev.* **88**, 55–66 (2021).
39. Jeong, M. H. et al. Protective activity of a novel resveratrol analogue, HS-1793, against DNA damage in <sup>137</sup>Cs-irradiated CHO-K1 cells. *J. Radiat. Res.* **55**, 464–475 (2014).
40. Firsov, A. M. et al. Protonophoric action of BAM15 on planar bilayers, liposomes, mitochondria, bacteria and neurons. *Bioelectrochemistry* **137**, 107673 (2021).
41. Spicer, J. et al. Safety, antitumor activity, and T-cell responses in a dose-ranging phase I trial of the oncolytic peptide LTX-315 in patients with solid tumors. *Clin. Cancer Res.* **27**, 2755–2763 (2021).
42. Liu, L. et al. Melatonin protects against focal cerebral ischemia–reperfusion injury in diabetic mice by ameliorating mitochondrial impairments: involvement of the Akt–SIRT3–SOD2 signaling pathway. *Aging* **13**, 16105–16123 (2021).
43. Liu, J. X. et al. Protection of procyanidin B2 on mitochondrial dynamics in sepsis associated acute kidney injury via promoting Nrf2 nuclear translocation. *Aging* **12**, 15638–15655 (2020).
44. Mihara, M. et al. p53 has a direct apoptogenic role at the mitochondria. *Mol. Cell* **11**, 577–590 (2003).
45. Baar, M. P. et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. *Cell* **169**, 132–147 (2017).
46. Ju, W. et al. Design and synthesis of novel mitochondria-targeted CDDO derivatives as potential anti-cancer agents. *Bioorg. Chem.* **115**, 105249 (2021).
47. Chen, F. et al. Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance. *Nat. Commun.* **9**, 4315 (2018).
48. Demaria, M. et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. *Cancer Discov.* **7**, 165–176 (2017).
49. Melisi, D. et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. *J. Natl Cancer Inst.* **103**, 1190–1204 (2011).
50. Xu, M. et al. Senolytics improve physical function and increase lifespan in old age. *Nat. Med.* **24**, 1246–1256 (2018).
51. Stoupi, S. et al. In vivo bioavailability, absorption, excretion, and pharmacokinetics of [<sup>14</sup>C]procyanidin B2 in male rats. *Drug Metab. Dispos.* **38**, 287–291 (2010).
52. Jorgensen, E. M., Marin, A. B. & Kennedy, J. A. Analysis of the oxidative degradation of proanthocyanidins under basic conditions. *J. Agric. Food Chem.* **52**, 2292–2296 (2004).
53. Partridge, L., Fuentealba, M. & Kennedy, B. K. The quest to slow ageing through drug discovery. *Nat. Rev. Drug Discov.* **19**, 513–532 (2020).
54. Liu, Y. et al. Expression of p16<sup>INK4a</sup> in peripheral blood T-cells is a biomarker of human aging. *Aging Cell* **8**, 439–448 (2009).
55. Zeng, Y. et al. Comparison of in vitro and in vivo antioxidant activities of six flavonoids with similar structures. *Antioxidants* **9**, 732 (2020).
56. Rodriguez-Ramiro, I., Martin, M. A., Ramos, S., Bravo, L. & Goya, L. Comparative effects of dietary flavanols on antioxidant defences and their response to oxidant-induced stress on Caco2 cells. *Eur. J. Nutr.* **50**, 313–322 (2011).
57. He, S. & Sharpless, N. E. Senescence in health and disease. *Cell* **169**, 1000–1011 (2017).
58. Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. *Nature* **583**, 127–132 (2020).
59. Childs, B. G. et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. *Science* **354**, 472–477 (2016).
60. Jeon, O. H. et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. *Nat. Med.* **23**, 775–781 (2017).
61. Riessland, M. et al. Loss of SATB1 induces p21-dependent cellular senescence in post-mitotic dopaminergic neurons. *Cell Stem Cell* **25**, 514–530 (2019).
62. Hou, Y. et al. Ageing as a risk factor for neurodegenerative disease. *Nat. Rev. Neurol.* **15**, 565–581 (2019).
63. Guerrero, A. et al. Cardiac glycosides are broad-spectrum senolytics. *Nat. Metab.* **1**, 1074–1088 (2019).
64. Triana-Martinez, F. et al. Identification and characterization of cardiac glycosides as senolytic compounds. *Nat. Commun.* **10**, 4731 (2019).
65. Lee, Y. R. et al. Metabolite profiling of rambutan (*Nephelium lappaceum* L.) seeds using UPLC–qTOF-MS/MS and senomorphic effects in aged human dermal fibroblasts. *Nutrients* **12**, 1430 (2020).
66. Perrott, K. M., Wiley, C. D., Desprez, P. Y. & Campisi, J. Apigenin suppresses the senescence-associated secretory phenotype and paracrine effects on breast cancer cells. *GeroScience* **39**, 161–173 (2017).
67. Lewinska, A. et al. AMPK-mediated senolytic and senostatic activity of quercetin surface functionalized Fe<sub>3</sub>O<sub>4</sub> nanoparticles during oxidant-induced senescence in human fibroblasts. *Redox Biol.* **28**, 101337 (2020).
68. Childs, B. G. et al. Senescent cells: an emerging target for diseases of ageing. *Nat. Rev. Drug Discov.* **16**, 718–735 (2017).
69. Schafer, M. J. et al. Cellular senescence mediates fibrotic pulmonary disease. *Nat. Commun.* **8**, 14532 (2017).
70. Cai, Y. et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. *Cell Res.* **30**, 574–589 (2020).
71. Nie, Y. & Sturzenbaum, S. R. Proanthocyanidins of natural origin: molecular mechanisms and implications for lipid disorder and aging-associated diseases. *Adv. Nutr.* **10**, 464–478 (2019).
72. Bae, J., Kumazoe, M., Murata, K., Fujimura, Y. & Tachibana, H. Procyanidin C1 inhibits melanoma cell growth by activating 67-kDa laminin receptor signaling. *Mol. Nutr. Food Res.* **64**, e1900986 (2020).
73. Ma, H. et al. Macrophages inhibit adipogenic differentiation of adipose tissue derived mesenchymal stem/stromal cells by producing pro-inflammatory cytokines. *Cell Biosci.* **10**, 88 (2020).
74. Finney, D. J. The adjustment for a natural response rate in probit analysis. *Ann. Appl. Biol.* **36**, 187–195 (1949).

75. Robinson, A. R. et al. Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging. *Redox Biol.* **17**, 259–273 (2018).
76. Krzywinski, M. & Altman, N. Power and sample size. *Nat. Methods* **10**, 1139–1140 (2013).

### Acknowledgements

We are grateful to members of the Sun laboratory for reagents, comments and other contributions to this project. This work was supported by grants from the National Key Research and Development Program of China (2020YFC2002800, 2016YFC1302400), the National Natural Science Foundation of China (81472709, 31671425, 31871380, 82130045) to Y.S., the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB39010500) to Y.S., funding from the Key Laboratory of Tissue Microenvironment and Tumor of the Chinese Academy of Sciences (201506, 201706, 202008) to Y.S., the Anti-Ageing Collaborative Program of SIBS and By-Health (C01201911260006) to Y.S., the University and Locality Collaborative Development Program of Yantai (2019XDRHXMRC08, 2020XDRHXMK02) to Y.S., and the US DoD PCRP (Idea Development Award PC111703) to Y.S.; the National Key Research and Development Program of China (2016YFA0100602, 2017YFA0103302) and the National Natural Science Foundation of China (92049304, 91749203, 82030039) to Z.J.; US NIH grants R37-AG013925 and P01 AG062413, the Connor Fund, Robert J. and Theresa W. Ryan and the Noaber Foundation to J.L.K.; and the National Natural Science Foundation of China (81370730, 81571512), the University and Locality Collaborative Development Program of Yantai (2021XDHZ082) and the Yantai Double Hundred Program to Q.F.

### Author contributions

Y.S. conceived this study, designed experiments and supervised the project. Q.X. performed most of the in vitro assays and some of the in vivo experiments and wrote part of the manuscript. Z.L. conducted HPLC–QTOF–MS/MS, provided data and performed preliminary analysis. H.L. performed some cell culture and drug treatment assays. Q.F. performed most of the preclinical studies. Y.W., X.L., R.H., X.Z., Z.J., J.C. and J.L.K. provided conceptual input or supervised a specific subset of experiments. Y.S. orchestrated data analysis and graphic presentation and finalized the manuscript. All authors critically read and commented on the final manuscript.

### Competing interests

By-Health funds research on senolytics in Y.S.'s laboratory. Y.S., Q.X., R.H. and X.Z. are named inventors on a technical patent related to senolytic screening and pharmacological evaluation (202011428651.2). Q.F. is the founder and CEO of Shandong Cellogene Pharmaceuticals, for which Y.S. serves as a scientific advisor. J.C. is a scientific founder of Unity Biotechnology, which develops senolytic therapies, and holds patents related to the induction and detection of senolysis. J.L.K. has financial interest related to this research, with patents on senolytic drugs held by the Mayo Clinic. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. The remaining authors declare no competing interests.

### Additional information

**Extended data** is available for this paper at <https://doi.org/10.1038/s42255-021-00491-8>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s42255-021-00491-8>.

**Correspondence and requests for materials** should be addressed to Yu Sun.


**Peer review information** *Nature Metabolism* thanks Manuel Collado, Valery Krizhanovsky and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary handling editor: Christoph Schmitt.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021




Extended Data Fig. 1 | See next page for caption.




**Extended Data Fig. 1 | *In vitro* screening of a natural product library with human stromal cells.** (a) Schematic workflow of cell-based screening strategy for a natural library of medicinal agents. (b) Quantification of cell survival of control (CTRL) and senescent (SEN) PSC27 after treatment with ABT-263 (1.25  $\mu$ M), ABT-737 (10  $\mu$ M) or Dasatinib (250 nM) combined with Quercetin (50  $\mu$ M) for 3 d. (c) Screening results after pharmacological assays. Library agents were assessed at a concentration of 3  $\mu$ g/ml with  $5.0 \times 10^3$  cells for 3 d. Hits were selected based on their ability to specifically kill senescent cells. Each blue dot represents a single agent as the mean of three replicates. Red rectangular region denotes potential candidates of senolytics in the case of TIS. (d) Appraisal of the effects of randomly selected agents (23 representative candidates out of 46 in the library, each applied at 1  $\mu$ g/ml) on the survival of CTRL and SEN cells. (e) Assessment of the effects of remaining agents (23 candidates out of 46 in the library, each applied at 1  $\mu$ g/ml) on the survival of CTRL and SEN cells. For all datasets, samples were collected for analyses 3 days after treatment with individual agents in culture condition. TIS, therapy-induced senescence. Data in b, d and e are shown as mean  $\pm$  SD and representative of 3 independent biological replicates, with *P* values calculated by a two-sided *t*-test. \*, *P* < 0.05; \*\*, *P* < 0.01.





Extended Data Fig. 2 | See next page for caption.


**Extended Data Fig. 2 | Bioinformatics profiling of the effect of GSE on genome-wide expression of senescent cells.** (a) Quantitative analysis of SASP factor expression at transcription level upon treatment of BLEO-induced senescent cells with different concentrations of GSE in culture. *P* values were calculated by one-way ANOVA with Tukey's multiple-comparison test. (b) Heatmap depicting the expression landscape of senescent cells and their counterparts exposed to GSE (0.1875  $\mu\text{g}/\text{ml}$ ). Note there were 2644 and 1472 genes, expression of which was significantly downregulated and upregulated by GSE, respectively. (c) Heatmap depicting the expression profiles of human genes in CTRL cells, SEN cells or SEN cells treated by GSE. According to the fold change of transcript expression, the top 50 genes are displayed. (d) GSEA plot of significant gene set indicative of a typical SASP. (e) GSEA plot of significant gene set associated with the activation of NF- $\kappa$ B signaling. For d and e, *P* values were calculated by one-way ANOVA with Tukey's *post hoc* comparison. (f) Immunoblot analysis of DNA damage repair signaling, p65 nuclear translocation and CXCL8 expression in PSC27 cells (CTRL or SEN) exposed to GSE treatment. L, a representative low concentration (0.1875  $\mu\text{g}/\text{ml}$ ). H, a representative high concentration (3.7500  $\mu\text{g}/\text{ml}$ ). Cellular senescence was induced by the genotoxic chemical bleomycin (BLEO), which causes a typical TIS. For all datasets, cells were collected for analyses 3 days after GSE treatment in culture condition. Data in a and f are representative of 3 independent biological replicates.



Extended Data Fig. 3 | See next page for caption.


**Extended Data Fig. 3 | Bioinformatics profiling of the effect of GSE on the intracellular signaling network of senescent cells.** (a) Mapping of protein-protein interaction (PPI) for BLEO-upregulated but GSE-downregulated genes by STRING program. (b-c) Column charts depicting the biological processes (BP) (b) and cellular components (CC) (c) pronouncedly associated with transcripts upregulated by BLEO but downregulated by GSE as revealed by GO analysis.





Extended Data Fig. 4 | See next page for caption.


**Extended Data Fig. 4 | *In vitro* cell assays identify PCC1 as a broad-spectrum senolytic.** (a) Representative images displaying SA- $\beta$ -Gal staining results after treatment of PSC27 cells with increasing concentrations of PCC1. Scale bar, 30  $\mu$ m. Data are representative of 3 independent experiments. (b) Senolytic activity appraisal by measuring the percentage of surviving senescent PSC27 cells induced by replicative exhaustion (RS) at increasing PCC1 concentrations. (c) Caspase 3/7 activity-based apoptotic evaluation of CTRL and RS cells treated by PCC1. (d) Senolytic activity assessment by determining the percentage of surviving senescent cells induced by oncogenic HRas<sup>G12V</sup> (OIS) at increasing PCC1 concentrations. For b and d, *P* values were calculated by two-sided *t*-test. (e) Caspase 3/7 activity-based apoptotic appraisal of CTRL and OIS cells treated by PCC1. (f-h) Quantification of the viability of cells in CTRL, TIS, RS and OIS groups treated by 100  $\mu$ M PCC1 for 3 d. (f), WI38. (g), HUVEC. (h), MSC. The significance of *P* values for the first concentration of PCC1 that differentiating the survival of CTRL and SEN cells was marked *per cell line*-based assay. For f, g and h, *P* values were calculated by one-way ANOVA with Tukey's multiple-comparison test. (i) Quantification of cell survival in CTRL and SEN populations after combined treatment of 100  $\mu$ M PCC1 with a ferroptosis inhibitor (liproxstatin-1), necroptosis inhibitor (Nec-1s), caspase-1 inhibitor (VX-765), or a pan-caspase inhibitor (QVD-O-Ph). Cell survival was presented as comparative data of different concentrations of chemicals relative to cells treated by the vehicle. *P* values were calculated by two-sided *t*-test. All data are shown as mean  $\pm$  SD, and are representative of 3 biological replicates. ^, *P* > 0.05. \*, *P* < 0.05. \*\*, *P* < 0.01. \*\*\*, *P* < 0.001. \*\*\*\*, *P* < 0.0001.



Extended Data Fig. 5 | See next page for caption.


**Extended Data Fig. 5 | Characterization of PCC1-induced apoptosis of senescent cells.** (a) Survival assays of PSC27 cells infected with lentivirus encoding shRNAs against indicated factors. Cells were exposed to PCC1 (100  $\mu$ M) 7 days after BLEO-caused senescence, for a 3-d period to induce apoptosis. SCR, scramble. *P* values were calculated by one-way ANOVA with Tukey's multiple-comparison test. (b) Immunoblot profiling Noxa expression in PSC27 cells infected with lentivirus encoding shRNAs specific for Noxa before treatment with different agents. (c) Immunoblot profiling Puma expression in PSC27 cells, in a workflow resembling that of Noxa. (d) Staining of ROS in senescent PSC27 cells with 2'-7'-dichlorodihydrofluorescein diacetate (DCFH-DA), a cell permeable fluorescent probe indicative of changes in redox state. Signals were measured in a 4-d time course starting from PCC treatment. Scale bar, 20  $\mu$ m. (e) Examination of ROS by DCFH-DA-staining. Cells were exposed to different agents 7 days after BLEO challenge, for a 3-day period. Staining with DCFH-DA was performed 1 day after addition of individual agents. Scale bar, 20  $\mu$ m. (f) Statistical comparison of ROS signal intensity measured for cells described in (e). (g) Apoptotic assay of PSC27 cells exposed to *in vitro* treatments described in (e) by examination of caspase 3/7 activity. Signals from DMSO treatment as a baseline, with indicated *P* values derived from comparison against PCC1-treated samples. Data are shown as mean  $\pm$  SD and derive from 3 biological replicates (*n* = 3 independent assays). *P* values were calculated by two-sided *t*-test. (h) Immunoblot of cytochrome c in cells exposed to PCC1. (i) Immunoblot of cytochrome c in cells exposed to PCB2. For (h) and (i), distribution of cytochrome c between mitochondria and cytoplasm was profiled by isolating mitochondria from cytosol supernatants at specialized timepoints (day 0-3 for h, and 3 for i) after procyanidin treatment. COX IV, mitochondrial marker. Data of b-d, h-i are representative of 3 independent experiments. Data of bar graphs (a and f) are shown as mean  $\pm$  SD and represent 3 biological replicates.  $\wedge$ , *P* > 0.05. \*, *P* < 0.05. \*\*, *P* < 0.01. \*\*\*, *P* < 0.001. \*\*\*\*, *P* < 0.0001.






Extended Data Fig. 6 | See next page for caption.

**Extended Data Fig. 6 | Schematic design of preclinical trial, expression analysis of the SASP and pathophysiological appraisal of treatments. (a)** Statistics of tumor end volumes. PC3 cells were xenografted alone or together with PSC27 to the hind flank of animals, with tumor volumes measured at the end of an 8-week period. **(b)** Cancer cells (PC3) alone or alongside stromal cells (PSC27) were inoculated subcutaneously to NOD/SCID males 2 weeks before chemotherapy. MIT was delivered via intravenous injection on the 1<sup>st</sup> day of each week starting from the 3<sup>rd</sup> week, then given every other week, totally 3 doses. PCC1 administered via *i.p.* starting from beginning of the 5<sup>th</sup> week, then once *per* 2 weeks. At the end of 8 weeks mice were sacrificed, tumor volume measured and tissues assessed. **(c)** Transcript analysis of canonical SASP factors (GM-CSF/MMP3/IL1 $\alpha$ ) and p16<sup>INK4a</sup> expressed in epithelial and stromal cells, respectively. Individual cell types isolated from tumor tissues via LCM. Data are representative of 3 biological replicates ( $n=10$  animals per group). Datasets are displayed as box-and-whisker plots, where a box extends from the 25th to 75th percentile with the median shown as a line in the middle, with whiskers indicating smallest and largest values. *P* values were calculated by two-sided *t*-test. **(d)** Heatmap depicting top genes (50) significantly upregulated in PSC27 xenografted subcutaneously to mice and induced senescent by MIT. Gene expression in animals experiencing MIT/PCC1 co-treatment also profiled, with transcript signals normalized to vehicle-treated group. Red stars, SASP factors. **(e)** Body weight determination performed on a weekly basis for immunodeficient mice. **(f)** Serum measurement of creatinine, urea, alkaline phosphatase (ALP), and alanine aminotransferase (ALT) with terminal bleeds (cardiac punctures) taken at the end of therapeutic regimens. For **a** and **c**, *P* values were calculated by two-sided *t*-test. For **e-f**, *P* values were calculated by one-way ANOVA with Tukey's multiple-comparison test. Data in **a**, **e** and **f** are shown as mean  $\pm$  SD and representative of 3 independent experiments. MIT, mitoxantrone. For each dataset,  $n=10$  *per* treatment arm.




**Extended Data Fig. 7 | PCC1 alleviates physical dysfunction of animals transplanted with senescent cells.** (a) Maximal walking speed (relative to the baseline) of 5-month-old C57BL/6J males at different time points post transplantation of  $1 \times 10^6$  SEN stromal cells and treatment with PCC1 or vehicle (V). (b) Hanging endurance (measured as sec x g) of 5-month-old C57BL/6J males at different time points as described in (a). Data are representative of 3 biological replicates ( $n = 10$  animals *per* group). Datasets are displayed as box-and-whisker plots, where a box extends from the 25th to 75th percentile with the median shown as a line in the middle, with whiskers indicating smallest and largest values. For **a-b**,  $P$  values were calculated by two-sided  $t$ -test.  $\wedge$ ,  $P > 0.05$ . \*,  $P < 0.05$ . \*\*,  $P < 0.01$ . \*\*\*,  $P < 0.001$ .



Extended Data Fig. 8 | See next page for caption.



**Extended Data Fig. 8 | Intermittent administration of PCC1 alleviates physical dysfunction of aged mice.** **(a)** Representative images of SA- $\beta$ -Gal staining of liver tissues from young (6 months of age) and aged males treated with vehicle or PCC1. Scale bar, 200  $\mu$ m. **(b)** Comparative statistics of SA- $\beta$ -Gal staining positivity of samples assayed in **(a)**. **(c)** Representative images of SA- $\beta$ -Gal staining of lung tissues from young and aged mice treated with vehicle or PCC1. Scale bar, 200  $\mu$ m. **(d)** Comparative statistics of SA- $\beta$ -Gal staining positivity of samples examined in **(c)**. **(e)** Representative images of SA- $\beta$ -Gal staining of prostate tissues from young and aged mice treated with vehicle or PCC1. Scale bar, 200  $\mu$ m. **(f)** Comparative statistics of SA- $\beta$ -Gal staining positivity of samples examined in **(e)**. **(g)** Quantification of body weight of animals as described in **(a)**. **(h)** Measurement of food intake of animals as described in **(a)**. Data in **g** and **h** are representative of 3 biological replicates ( $n = 10$  animals *per* group). Datasets are displayed as box-and-whisker plots, where a box extends from the 25th to 75th percentile with the median shown as a line in the middle, with whiskers indicating smallest and largest values. Data in bar graphs **(b, d and f)** are shown as mean  $\pm$  SD ( $n = 5$  animals *per* group) and representative of 3 independent experiments. For **b, d, f, g** and **h**,  $P$  values were calculated by two-sided  $t$ -test.  $\hat{}$ ,  $P > 0.05$ . \*,  $P < 0.05$ . \*\*,  $P < 0.01$ . \*\*\*,  $P < 0.001$ .



Extended Data Fig. 9 | See next page for caption.

**Extended Data Fig. 9 | Late life intervention with PCC1 does not alter the cause of death, but restrains the SASP and reduces oxidative stress. (a-b)**

Pie charts depicting the ultimate causes of death of C57BL/6J mice (males and females) that had undergone vehicle (a) or PCC1 (b) biweekly treatment starting from 24-27 months of age. Note there was no significant difference between vehicle- and PCC1-treated groups upon analysis using either Chi-square or Fisher's exact tests. (c-e) qRT-PCR profiling of the SASP and senescence marker expression in tissues of solid organs, including liver (c), lung (d) and prostate (e) collected from young (6-month-old, untreated), aged (24-27-month-old) vehicle-treated and aged (24-27-month-old) PCC1-treated animals, respectively. (f) Measurement of circulating levels of hallmark SASP factors IL6, CSF2 and MCP-1 in mouse blood by ELISA assays. (g) Quantification of SASP and senescence marker expression in CD3<sup>+</sup> peripheral T cells of experimental mice described in c-f. (h) Examination of 4-hydroxynonenal (HNE) adducts, a marker of lipid peroxidation and oxidative stress by ELISA measurement with tissue lysates of the liver. (i) Determination of the ratio of reduced (GSH) to oxidized (GSSG) glutathione measured as an index oxidative stress. Data are shown as mean  $\pm$  SD and derive from 3 biological replicates ( $n=3$  independent assays for c-i).  $P$  values were calculated by two-sided  $t$ -test.  $\hat{}$ ,  $P > 0.05$ . \*,  $P < 0.05$ . \*\*,  $P < 0.01$ . \*\*\*,  $P < 0.001$ .

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

IN Cell Analyzer 2500HS GE Healthcare  
 QuantStudio Real-Time PCR Software v1.1 Applied Biosystems  
 Flow cytometry: Beckman CytoFLEX LX, CytExpert (v 1.2)  
 Mass spectrometry: Nexera X2 LC-40 (SHIMADZU) coupled to AB SCIEX TripleTOF 6600 LC/MS/MS system (SCIEX), Analyst TF (v 1.7.1)  
 Hematology assay: Celltac Alpha MEK-6400 series hematology analyzers (Nihon Kohden)  
 Microsoft Excel 2016 (version 16.16.13)

Data analysis

GraphPad Prism 8 (version 8.3.0)  
 FlowJo (v 10.6.2)  
 Image J (v 1.52p)  
 FASTQC (v 0.11.5)  
 GSEA (v 4.1.0)  
 MSigDB (v 7.4)  
 Tophat (v 2.0.11)  
 Ensembl (v 72) gene annotation  
 NetworkAnalyst (v 3.0)  
 STRING (v 11.0)  
 FUNRICH (v 3)  
 Ingenuity Pathway Analysis (v 2020.12)  
 PANTHER (v 16.0)

R packages (v 4.0.3) from CRAN and Bioconductor:  
 custom R v 4.0 scripts  
 annotate (v 1.56.2)



```

ensemblDb (v 2.2.2)
edgeR (v 3.22.3)
fdrtool (v 1.2.16)
Bedtools2 (v 2.26.0)
Bowtie (v 2.2.2)
DESeq2 (v 1.18.1)
ggplot2 (v 3.1.0)
ggrepel (v 0.8.0)
gplots (v 3.0.1)
graph (v 1.56.0)
gridExtra (v 2.3)

pd.hta.2.0 (v 3.12.2)
pheatmap (v 1.0.10)
plotly (v 4.8.0)
plotrix (v 3.7.4)
plyr (v 1.8.4)
preseqR (v 3.1.2)

```

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Statistical source data underlying some key experiments are provided in separate Excel files. Unprocessed immunoblots are provided as source data. All data supporting the findings of the study are available from the corresponding author upon reasonable request. Mass spectrometry data associated with this study will be submitted to the public depository (the Mass Spectrometry Interactive Virtual Environment at <https://massive.ucsd.edu>, which serves as a data hub for computational mass spectrometry with open mzTab format data conversion function currently in construction). The RNA-seq data are deposited in publicly accessible sources and available at the GEO database with accession codes GSE156301, GSE164012 and GSE178376. Fig. 3, Extended Data Fig. 2 and 6, and Supplementary Fig. 5 are associated with the RNA-seq data (raw and processed data accessible through GEO). Extended Data Fig. 4f-h are associated with complete analysis results presented in Supplementary Table 3. Other source data and statistics for corresponding figures are provided in Supplementary Information or Source Data sections.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample size was not determined by specific statistical methods a priori, but were based on variability of associated assays. The sample sizes are similar to those reported in previous publications with comparable experiments (Chang et al., Nature Medicine. 2016; Zhang et al., Nature Communications. 2018; Xu et al., Nature Medicine. 2018; Guerrero et al., Nature Metabolism. 2019). We did not focus on a specific effect-size and performed a discovery study, including all available samples that passed QC into analysis. To our knowledge, a comparative senescence-cell targeting senolytics investigation of plant-derived procyanidins has not been previously undertaken.
Data exclusions	All data were included, without specific exclusions.
Replication	All experiments were reproducible. Every figure states how many times the related experiment was performed with similar results. All data presented were from independent biological replicates or independent experiments. All attempts at replication were successful.
Randomization	For high-throughput data acquisition and database generation, samples were randomized between batches to account for possible batch-effect. Stringent inclusion criteria were set to account for other possible confounding variables. For preclinical experiments, animals were randomly assigned to each individual groups.
Blinding	The investigators were not blinded to sample group allocations due to the fact that the genotypes of human primary cells, needed to be carefully documented by the investigators, so blinding was not always possible during experimental setup. When feasible, data analysis was performed blind, including RNA and protein preparation, q-PCR and immunoblots, immunofluorescence staining, RNA-seq library preparation, bioinformatics profiling, evaluation of histological sections from preclinical biospecimens, for which all data acquisition was performed blinded

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

### Antibodies used

The following antibodies were purchased from the indicated suppliers and used for immunoblotting (if not stated; or otherwise, immunofluorescence staining or immunohistochemistry staining, as stated separately) at indicated concentrations: rabbit monoclonal anti-p-ATM (Abways cat. no. CY5111, no clone name), 1:1000; rabbit monoclonal anti-ATM (Abways cat. no. CY5207, no clone name), 1:1000; rabbit monoclonal anti-γH2AX (Cell Signaling cat. no. 9718, clone 20E3), 1:500; rabbit monoclonal anti-H2AX (Cell Signaling, cat. no. 7631, clone D17A3), 1:1000; rabbit polyclonal anti-CXCL8 (Proteintech cat. no. 27095-1-AP), 1:500; mouse monoclonal anti-p53 (Cell Signaling cat. no. 2524, clone 1C12), 1:500 (for both immunoblotting and immunofluorescence staining); rabbit polyclonal anti-Lamin A/C (Proteintech cat. no. 10298-1-AP), 1:1000; mouse monoclonal anti-BrdU (Cell Signaling cat. no. 5292, clone Bu20a), 1:1000; rabbit polyclonal anti-p-p38 (R&D cat. no. AF869), 1:2000; rabbit polyclonal anti-p38 (Cell signaling cat. no. 9212), 1:1000; rabbit polyclonal anti-p-AKT (Abcam cat. no. ab8932), 1:1000; rabbit polyclonal anti-AKT (Proteintech cat. no. 10176-1-AP), 1:500; mouse monoclonal anti-NF-κB p65 (Santa Cruz cat. no. sc-8008, clone F-6), 1:1000; rabbit polyclonal anti-NOXA (Abways cat. no. CY6774), 1:1000; rabbit polyclonal anti-PUMA (Abways cat. no. CY5460), 1:1000; rabbit polyclonal anti-Bcl-2 (Abways cat. no. CY6717), 1:1000; rabbit monoclonal anti-Bcl-xL (Cell Signaling cat. no. 2764, clone 54H6), 1:1000; rabbit polyclonal anti-Bax (Cell Signaling cat. no. 2772), 1:1000; rabbit polyclonal anti-Cytochrome c (Proteintech cat. no. 10993-1-AP), 1:1000; rabbit polyclonal anti-COX IV (ABclonal cat. no. A6564), 1:500 (for both immunoblotting and immunofluorescence staining); rabbit monoclonal anti-Caspase 3 (cleaved) (Cell Signaling cat. no. 9661, clone Asp175), 1:1000 (or 1:250 for immunohistochemistry staining); rabbit monoclonal anti-Caspase 3 (total) (Cell Signaling cat. no. 9662, no clone name), 1:1000; mouse monoclonal anti-p16 (BD Biosciences cat. no. 554079, clone G175-1239), 1:500 (for immunofluorescence staining); goat polyclonal anti-rabbit IgG H&L (HRP) (abcam cat. no. ab6721), 1:500 or goat polyclonal anti-mouse IgG H&L (HRP) (abcam cat. no. ab6789), 1:500; goat polyclonal to rabbit (or mouse) IgG Alexa Fluor 488 or 594-conjugated secondary (abcam cat. no. ab150077, ab150080, ab150113, ab150116), 1:400 (for immunofluorescence staining); mouse monoclonal anti-β-actin (Proteintech cat. no. 66009-1-Ig, clone 2D4H5), 1:4000; rabbit monoclonal anti-GAPDH (Abways cat. no. AB0037, no clone name), 1:2000.

### Validation

Antibody validations were performed by antibody suppliers per quality assurance literature provided by each supplier for applications used in this study (see links below).

rabbit monoclonal anti-p-ATM (Abways cat. no. CY5111), immunoblotting  
<http://www.abways.com/showproduct.asp?cid=CY5111>  
 rabbit monoclonal anti-ATM (Abways cat. no. CY5207), immunoblotting  
<http://www.abways.com/showproduct.asp?cid=CY5207>  
 rabbit monoclonal anti-γH2AX (Cell Signaling cat. no. 9718), immunoblotting  
[https://www.cellsignal.cn/products/primary-antibodies/phospho-histone-h2a-x-ser139-20e3-rabbit-mab/9718?site-search-type=Products&N=4294956287&Ntt=9718&fromPage=plp&\\_requestid=6426762](https://www.cellsignal.cn/products/primary-antibodies/phospho-histone-h2a-x-ser139-20e3-rabbit-mab/9718?site-search-type=Products&N=4294956287&Ntt=9718&fromPage=plp&_requestid=6426762)  
 rabbit monoclonal anti-H2AX (Cell Signaling cat. no. 7631), immunoblotting  
[https://www.cellsignal.cn/products/primary-antibodies/histone-h2a-x-d17a3-xp-rabbit-mab/7631?site-search-type=Products&N=4294956287&Ntt=7631&fromPage=plp&\\_requestid=2864687](https://www.cellsignal.cn/products/primary-antibodies/histone-h2a-x-d17a3-xp-rabbit-mab/7631?site-search-type=Products&N=4294956287&Ntt=7631&fromPage=plp&_requestid=2864687)  
 rabbit polyclonal anti-CXCL8 (Proteintech cat. no. 27095-1-AP), immunoblotting  
<https://www.ptgcn.com/products/CXCL8-IL8-Antibody-27095-1-AP.htm>  
 mouse monoclonal anti-p53 (Cell Signaling cat. no. 2524), immunoblotting and immunofluorescence staining  
[https://www.cellsignal.cn/products/primary-antibodies/p53-1c12-mouse-mab/2524?site-search-type=Products&N=4294956287&Ntt=2524&fromPage=plp&\\_requestid=2865145](https://www.cellsignal.cn/products/primary-antibodies/p53-1c12-mouse-mab/2524?site-search-type=Products&N=4294956287&Ntt=2524&fromPage=plp&_requestid=2865145)  
 rabbit polyclonal anti-Lamin A/C (Proteintech cat. no. 10298-1-AP), immunoblotting  
<http://www.ptgcn.com/products/lamin-A-Antibody-10298-1-AP.htm>  
 mouse monoclonal anti-BrdU (Cell Signaling cat. no. 5292), immunoblotting  
<https://www.cellsignal.com/products/primary-antibodies/brdu-bu20a-mouse-mab/5292>  
 rabbit polyclonal anti-p-p38 (R&D cat. no. AF869), immunoblotting  
[https://www.rndsystems.com/cn/products/human-mouse-rat-phospho-p38-map-kinase-t180-y182-antibody\\_af869](https://www.rndsystems.com/cn/products/human-mouse-rat-phospho-p38-map-kinase-t180-y182-antibody_af869)  
 rabbit polyclonal anti-p38 (Cell Signaling cat. no. 9212), immunoblotting  
<https://www.cellsignal.com/products/primary-antibodies/p38-mapk-antibody/9212>  
 rabbit polyclonal anti-p-AKT (Abcam cat. no. ab8932), immunoblotting  
<https://www.abcam.cn/akt1-phospho-s473-antibody-ab8932.html>  
 rabbit polyclonal anti-AKT (Proteintech cat. no. 10176-1-AP), immunoblotting

<http://www.ptgcn.com/products/AKT-Antibody-10176-2-AP.htm>  
 mouse monoclonal anti-NF- $\kappa$ B p65 (Santa Cruz cat. no. sc-8008), immunoblotting  
<https://www.scbt.com/p/nfkappab-p65-antibody-f-6?requestFrom=search>  
 rabbit polyclonal anti-NOXA (Abways cat. no. CY6774), immunoblotting  
<http://www.abways.com/showproduct.asp?cid=CY6774>  
 rabbit polyclonal anti-PUMA (Abways cat. no. CY5460), immunoblotting  
<http://www.abways.com/showproduct.asp?cid=CY5460>  
 rabbit polyclonal anti-Bcl-2 (Abways cat. no. CY6717), immunoblotting  
<http://www.abways.com/showproduct.asp?cid=CY6717>  
 rabbit monoclonal anti-Bcl-xL (Cell Signaling cat. no. 2764), immunoblotting  
<https://www.cellsignal.com/products/primary-antibodies/bcl-xl-54h6-rabbit-mab/2764>  
 rabbit polyclonal anti-Bax (Cell Signaling cat. no. 2772), immunoblotting  
<https://www.cellsignal.com/products/primary-antibodies/bax-antibody/2772>  
 rabbit polyclonal anti-Cytochrome c (Proteintech cat. no. 10993-1-AP), immunoblotting  
<https://www.ptglab.com/products/CYCS-Antibody-10993-1-AP.htm>  
 rabbit polyclonal anti-COX IV (ABclonal cat. no. A6564), immunoblotting and immunofluorescence staining  
<https://abclonal.com.cn/catalog/A6564>  
 rabbit monoclonal cleaved-Caspase 3 (Cell Signaling cat. no. 9661), immunoblotting and immunohistochemistry staining  
<https://www.cellsignal.cn/products/primary-antibodies/cleaved-caspase-3-asp175-antibody/9661>  
 rabbit monoclonal Caspase 3 (Cell Signaling cat. no. 9662), immunoblotting  
<https://www.cellsignal.cn/products/primary-antibodies/caspase-3-antibody/9662?site-search-type=Products&N=4294956287&Ntt=9662&fromPage=plp>  
 mouse monoclonal anti-p16 (BD Biosciences cat. no. 554079), immunofluorescence staining  
<https://www.citeab.com/antibodies/2411943-554079-bd-pharmingen-purified-mouse-anti-human-p16>  
 goat polyclonal anti-rabbit IgG H&L (HRP) (abcam cat. no. ab6721), immunoblotting  
<https://www.abcam.com/goat-rabbit-igg-hl-hrp-ab6721.html>  
 goat polyclonal anti-mouse IgG H&L (HRP) (abcam cat. no. ab6789), immunoblotting  
<https://www.abcam.com/goat-mouse-igg-hl-hrp-ab6789.html>  
 goat polyclonal to rabbit (or mouse) IgG Alexa Fluor 488 or 594-conjugated secondary (abcam cat. no. ab150077, ab150080, ab150113, ab150116), immunofluorescence staining  
<https://www.abcam.com/goat-rabbit-igg-hl-alexa-fluor-488-ab150077.html>  
<https://www.abcam.com/goat-rabbit-igg-hl-alexa-fluor-594-ab150080.html>  
<https://www.abcam.com/goat-mouse-igg-hl-alexa-fluor-488-ab150113.html>  
<https://www.abcam.com/goat-mouse-igg-hl-alexa-fluor-594-ab150116.html>  
 mouse monoclonal anti- $\beta$ -actin (Proteintech cat. no. 66009-1-Ig), immunoblotting  
<https://www.ptgcn.com/products/Pan-Actin-Antibody-66009-1-Ig.htm>  
 rabbit monoclonal anti-GAPDH (Abways cat. no. AB0037), immunoblotting  
<http://www.abways.com/showproduct.asp?cid=AB0037>

Anti-p-ATM rabbit monoclonal, Abways, cat. no. CY5111. Validated by the company and the following publication: Boyi Zhang, Da Fu, Qixia Xu, et al. The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. *Nat Commun.* 2018 Apr 30;9(1):1723. doi: 10.1038/s41467-018-04010-4.

Anti-ATM rabbit monoclonal, Abways, cat. no. CY5207. Validated by the company and the following publication: Boyi Zhang, Da Fu, Qixia Xu, et al. The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. *Nat Commun.* 2018 Apr 30;9(1):1723. doi: 10.1038/s41467-018-04010-4.

Anti- $\gamma$ H2AX rabbit monoclonal, Cell Signaling, cat. no. 9718. Validated by the company and the following publication: Chan EM, Shibue T, McFarland JM, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. *Nature.* 2019 Apr;568(7753):551-556. doi: 10.1038/s41586-019-1102-x.

Anti-H2AX rabbit monoclonal, Cell Signaling, cat. no. 7631. Validated by the company and the following publication: Nilay S Sethi, Osamu Kikuchi, Gina N Duronio, et al. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. *Nat Genet.* 2020 Feb;52(2):219-230. doi: 10.1038/s41588-019-0574-9.

Anti-CXCL8 rabbit polyclonal, Proteintech, cat. no. 27095-1-AP. Validated by the company and the following publication: Zheng T, Ma G, Tang M, et al. IL-8 secreted from M2 macrophages promoted prostate tumorigenesis via STAT3/MALAT1 pathway. *Int J Mol Sci.* 2018 Dec 27;20(1):98. doi: 10.3390/ijms20010098.

Anti-p53 mouse monoclonal, Cell Signaling, cat. no. 2524. Validated by the company and the following publication: Hao Guo, Wei-Chun Chou, Yunjia Lai, et al. Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites. *Science.* 2020 Oct 30;370(6516):eaay9097. doi: 10.1126/science.aay9097.

Anti-Lamin A/C rabbit polyclonal, Proteintech cat. no. 10298-1-AP. Validated by the company and the following publication: Jiao Yang, Xiaoman Zhang, Zheling Chen, et al. Angiotensin-p130 inhibits  $\beta$ -catenin stability by competing with Axin for binding to tankyrase in breast cancer. *Cell Death Dis.* 2019 Feb 21;10(3):179. doi: 10.1038/s41419-019-1427-2.

Anti-BrdU mouse monoclonal, Cell Signaling, cat. no. 5292. Validated by the company and the following publication: Boyi Zhang, Da Fu, Qixia Xu, et al. The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. *Nat Commun.* 2018 Apr 30;9(1):1723. doi: 10.1038/s41467-018-04010-4.

Anti-p-p38 rabbit polyclonal, R&D cat. no. AF869. Validated by the company and the following publication: Uwe Schlomann, Garrit Koller, Catharina Conrad, et al. ADAM8 as a drug target in pancreatic cancer. *Nat Commun.* 2015 Jan 28;6:6175. doi: 10.1038/ncomms7175.

Anti-p38 rabbit polyclonal, Cell Signaling, cat. no. 9212. Validated by the company and the following publication: Cuicui Wang, Jie

Shen, Jun Ying, et al. FoxO1 is a crucial mediator of TGF- $\beta$ /TAK1 signaling and protects against osteoarthritis by maintaining articular cartilage homeostasis. *Proc Natl Acad Sci U S A*. 2020 Dec 1;117(48):30488-30497. doi: 10.1073/pnas.2017056117.

Anti-p-AKT rabbit polyclonal, Abcam cat. no. ab8932. Validated by the company and the following publication: Huaying Dong, Jianguo Hu, Kejian Zou, et al. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer. *Mol Cancer*. 2019 Jan 8;18(1):3. doi: 10.1186/s12943-018-0931-9.

Anti-AKT rabbit polyclonal, Proteintech cat. no. 10176-1-AP. Validated by the company and the following publication: Dalong Cao, Zihao Qi, Yangyang Pang, et al. Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer. *Cancer Res*. 2019 May 15;79(10):2604-2618. doi: 10.1158/0008-5472.CAN-18-3842.

Anti-NF- $\kappa$ B p65 mouse monoclonal, Santa Cruz cat. no. sc-8008. Validated by the company and the following publication: Jinlin Zhao, Xin Wang, Zeyun Mi, et al. STAT3/miR-135b/NF- $\kappa$ B axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer. *Cell Death Dis*. 2021 May 14;12(5):493. doi: 10.1038/s41419-021-03773-x.

Anti-NOXA rabbit monoclonal, Abways cat. no. CY6774. Validated by the company.

Anti-PUMA rabbit monoclonal, Abways cat. no. CY5460. Validated by the company.

Anti-Bcl-2 rabbit monoclonal, Abways cat. no. CY6717. Validated by the company and the following publication: Jianing Li, Liangliang Zheng, Xue Wang, et al. Taurine protects INS-1 cells from apoptosis induced by Di(2-ethylhexyl) phthalate via reducing oxidative stress and autophagy. *Toxicol Mech Methods*. 2019 Jul;29(6):445-456. doi: 10.1080/15376516.2019.1588931.

Anti-Bcl-xL rabbit monoclonal, Cell Signaling cat. no. 2764. Validated by the company and the following publication: Yan Zhou, Tao Tao, Guangjie Liu, et al. TRAF3 mediates neuronal apoptosis in early brain injury following subarachnoid hemorrhage via targeting TAK1-dependent MAPKs and NF- $\kappa$ B pathways. *Cell Death Dis*. 2021 Jan 7;12(1):10. doi: 10.1038/s41419-020-03278-z.

Anti-Bax rabbit polyclonal, Cell Signaling cat. no. 2772. Validated by the company and the following publication: Valentina Montagnani, Luisa Maresca, Alessandro Apollo, et al. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis. *J Biol Chem*. 2020 Nov 20;295(47):16058-16071. doi: 10.1074/jbc.RA120.014615.

Anti-Cytochrome c rabbit polyclonal, Proteintech cat. no. 10993-1-AP. Validated by the company and the following publication: Xi-Gong Li, Jun-Hua Du, Yang Lu, et al. Neuroprotective effects of rapamycin on spinal cord injury in rats by increasing autophagy and Akt signaling. *Neural Regen Res*. 2019 Apr;14(4):721-727. doi: 10.4103/1673-5374.247476.

Anti-COX IV rabbit polyclonal, Abclonal cat. no. A6564. Validated by the company and the following publication: Huazhang Zhu, Weizhen Zhang, Yingying Zhao, et al. GSK3 $\beta$ -mediated tau hyperphosphorylation triggers diabetic retinal neurodegeneration by disrupting synaptic and mitochondrial functions. *Mol Neurodegener*. 2018 Nov 22;13(1):62. doi: 10.1186/s13024-018-0295-z.

Anti-Caspase 3 (cleaved) rabbit monoclonal, Cell Signaling, cat. no. 9661. Validated by the company and the following publication: Zhou W, Chen C, Shi Y, et al. Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy. *Cell Stem Cell*. 2017 Nov 2;21(5):591-603.e4. doi: 10.1016/j.stem.

Anti-Caspase 3 (total) rabbit monoclonal, Cell Signaling, cat. no. 9662. Validated by the company and the following publication: Donato V, Bonora M, Simoneschi D, et al. The TDH-GCN5L1-Fbxo15-KBP axis limits mitochondrial biogenesis in mouse embryonic stem cells. *Nat Cell Biol*. 2017 Apr;19(4):341-351. doi: 10.1038/ncb3491.

Anti-p16 mouse monoclonal, BD Biosciences cat. no. 554079. Validated by the company and following publication: Yann Deleye, Alexia Karen Cotte, Sarah Anissa Hannou, et al. CDKN2A/p16INK4a suppresses hepatic fatty acid oxidation through the AMPK $\alpha$ -SIRT1-PPAR $\alpha$  signaling pathway. *J Biol Chem*. 2020 Dec 11;295(50):17310-17322. doi: 10.1074/jbc.RA120.012543.

Goat polyclonal anti-rabbit IgG H&L (HRP) (abcam cat. no. ab6721). Validated by the company and following publication: Tian Y, Zhong L, Gao S, et al. LncRNA LINC00974 downregulates miR-122 to upregulate RhoA in oral squamous cell carcinoma. *Cancer Biother Radiopharm*. 2021 Feb;36(1):18-22. doi: 10.1089/cbr.2019.2907.

Goat polyclonal anti-mouse IgG H&L (HRP) (abcam cat. no. ab6789). Validated by the company and following publication: Jin K, Wen Z, Wu B, et al. NOTCH-induced rerouting of endosomal trafficking disables regulatory T cells in vasculitis. *J Clin Invest*. 2021 Jan 4;131(1):e136042. doi: 10.1172/JCI136042.

Goat polyclonal to rabbit (or mouse) IgG Alexa Fluor 488 or 594-conjugated secondary, abcam cat. no. ab150077, ab150080, ab150113, ab150116. Validated by the company and the following publication: Boyi Zhang, Qilai Long, Shanshan Wu, et al. KDM4 orchestrates epigenomic remodeling of senescent cells and potentiates the senescence-associated secretory phenotype. *Nat Aging*. 2021 May;1(5):454-472. doi: 10.1038/s43587-021-00063-1.

Anti- $\beta$ -actin mouse monoclonal, Proteintech cat. no. 66009-1-Ig. Validated by the company and the following publication: Damaris N Lorenzo and Vann Bennett. Cell-autonomous adiposity through increased cell surface GLUT4 due to ankyrin-B deficiency. *Proc Natl Acad Sci U S A*. 2017 Nov 28;114(48):12743-12748. doi: 10.1073/pnas.1708865114.

Anti-GAPDH rabbit monoclonal, Abways cat. no. AB0037. Validated by the company and the following publication: Boyi Zhang, Qilai Long, Shanshan Wu, et al. KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence-Associated Secretory Phenotype. *Nat Aging*. 2021 May;1(5):454-472. doi: 10.1038/s43587-021-00063-1.



## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	Primary normal human stromal cell line PSC27 was a kind gift (no commercial yet) of Dr. Peter Nelson (FHCRC) as described in references 14 and 15. Primary human fetal lung fibroblast line WI38 and primary human umbilical vein endothelial cell line HUVEC were purchased from ATCC, and maintained in DMEM and F-12K Medium, respectively, as recommended by the provider. Primary mesenchymal stem cell line MSC was isolated from human umbilical vein tissues and cultured in MSC complete media with 10 µg/ml recombinant human insulin as described in reference 73.
Authentication	All human cell lines were authenticated by genomic DNA profiling assays (STR) performed by XP Biomed.
Mycoplasma contamination	All cell lines in this study were tested negative for mycoplasma contamination.
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	None of the cell lines used in this study is present in the database of commonly misidentified cell lines.

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals	Nod-obese diabetic and severe combined immunodeficiency (NOD-SCID) male mice and wild type C57BL/6J male mice (Nanjing Model Animal Center, China) of 6-8 weeks old were housed and maintained in accordance with animal guidelines of Shanghai Institute of Nutrition and Health. All experimental mice were used and housed (22-25 C, 30% humidity) under 12 h light/12 h dark cycle (6 am-6 pm) with a standard rodent chow diet (SLOD, PicoLab).
Wild animals	No wild animals were used in this study.
Field-collected samples	This study did not involve field-collected samples.
Ethics oversight	All animal experiments were conducted in compliance with NIH Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011) and the ARRIVE guidelines, and were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Washington and an equivalent committee of Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation	Control and/or drug-treated cells were first trypsinized from culture flasks or dishes, simply rinsed and resuspended in PBS before counted by trypan blue dye-exclusion method. Briefly, cells were resuspended in Annexin V-FITC (195 µl) to thoroughly disperse, then treated with Annexin V-FITC (5 µl) and Propidium Iodide (PI, 10 µl) to stain at room temperature, with light-shielded for 10-20 min, then incubated on ice. Samples were then sent to flow device for analysis. Annexin V-FITC gives green fluorescence, while PI emits as red signals.
Instrument	Beckman Gallios flow cytometer (Beckman, CytoFLEX LX)
Software	CytExpert (v 1.2) and FlowJo software (FlowJo 10.6.2)
Cell population abundance	Totally 5-6 million cells were used for sorting per sample.
Gating strategy	FSC-A versus SSC-A was initially applied to the gate for lymphocytes (main targets). Cells were gated on single cells using FSC-A versus FSC-H and then used for PI and Annexin V-FITC to make subsequent gates. Cells were correspondingly gated for FITC fluorescence against PI fluorescence signals. Live cells were gated as FITC-PI-(Q4), apoptotic cells were gated as FITC+PI+ (Q2) or FITC+PI-(Q3).

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.